American Well (AMWL) 10-K 28 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 15, 2022
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	AMWL
Entity Registrant Name	American Well Corporation
Entity Central Index Key	0001393584
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Security Exchange Name	NYSE
Title of 12(b) Security	Class A common stock, par value of $0.01 per share
Entity File Number	001-39515
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5009396
Entity Address, Address Line One	75 State Street
Entity Address, Address Line Two	26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	204-3500
Entity Public Float	$ 2.4
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Boston, Massachusetts, United States
Documents Incorporated by Reference	The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the Registrant’s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		230,368,903
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		27,390,397
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 746,416	$ 941,616
Investments		99,963
Restricted cash	0	1,095
Accounts receivable ($2,054 and $12,053, from related parties and net of allowances of $1,809 and $1,556, respectively)	51,375	45,296
Inventories	7,530	9,128
Deferred contract acquisition costs	1,697	2,134
Prepaid expenses and other current assets	20,278	14,055
Total current assets	827,296	1,113,287
Restricted cash	795	0
Property and equipment, net	2,235	3,836
Goodwill	442,761	193,877
Intangibles assets, net	152,409	55,528
Operating lease right-of-use asset	16,422	6,609
Deferred contract acquisition costs, net of current portion	2,028	1,327
Other assets	1,722	1,430
Investment in minority owned joint venture	168	752
Total assets	1,445,836	1,376,646
Current liabilities:
Accounts payable	12,156	5,797
Accrued expenses and other current liabilities	58,711	42,135
Operating lease liability, current	1,918	6,357
Deferred revenue ($1,860 and $14,421 from related parties, respectively)	68,841	66,693
Total current liabilities	141,626	120,982
Other long-term liabilities	5,136	64
Contingent consideration liabilities, net of current portion	16,450
Operating lease liability, net of current portion	14,694	1,296
Deferred revenue, net of current portion ($22 and $486 from related parties, respectively)	7,055	8,107
Total liabilities	184,961	130,449
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2021 and as of December 31, 2020
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 229,402,453 and 201,488,097 shares issued, and 229,402,453 and 200,751,168 shares outstanding, respectively; 100,000,000 Class B shares authorized, 26,913,579 and 30,427,128 shares issued, and 26,913,579 and 29,297,382 shares outstanding, respectively; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of December 31, 2021 and December 31, 2020	2,620	2,357
Treasury stock, no shares and 1,866,675 shares as of December 31, 2021 and December 31, 2020, respectively		(37,568)
Additional paid-in capital	2,054,275	1,841,405
Accumulated other comprehensive income (loss)	(6,353)	297
Accumulated deficit	(811,284)	(582,359)
Total American Well Corporation stockholders’ equity	1,239,258	1,224,132
Non-controlling interest	21,617	22,065
Total stockholders’ equity	1,260,875	1,246,197
Total liabilities and stockholders’ equity	$ 1,445,836	$ 1,376,646

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable from related parties	$ 2,054	$ 12,053
Accounts receivable net of allowances	1,809	1,556
Deferred revenue from related parties current	1,860	14,421
Deferred revenue from related parties non current	$ 22	$ 486
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	261,871,587
Common Stock, Shares, Outstanding	261,871,587
Treasury Stock, Shares	0	1,866,675
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	229,402,453	201,488,097
Common Stock, Shares, Outstanding	229,402,453	200,751,168
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	26,913,579	30,427,128
Common Stock, Shares, Outstanding	26,913,579	29,297,382
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue
($12,045, $60,839 and $36,411 from related parties, respectively)	$ 252,789	$ 245,265	$ 148,857
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	148,474	156,790	79,976
Research and development	106,594	84,412	53,941
Sales and marketing	66,154	55,095	47,672
General and administrative	94,624	166,246	54,211
Depreciation and amortization expense	16,089	10,153	7,761
Total costs and operating expenses	431,935	472,696	243,561
Loss from operations	(179,146)	(227,431)	(94,704)
Interest income and other income (expense), net	120	1,632	5,535
Loss before benefit (expense) from income taxes and loss from equity method investment	(179,026)	(225,799)	(89,169)
Benefit (expense) from income taxes	5,376	(639)	803
Loss from equity method investment	(3,132)	(2,188)
Net loss	(176,782)	(228,626)	(88,366)
Net loss attributable to non-controlling interest	(448)	(4,194)	(1,176)
Net loss attributable to American Well Corporation	$ (176,334)	$ (224,432)	$ (87,190)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.69)	$ (2.27)	$ (2.12)
Weighted-average common shares outstanding, basic and diluted	254,068,942	99,044,312	41,138,798
Net loss	$ (176,782)	$ (228,626)	$ (88,366)
Other comprehensive income (loss), net of tax:
Unrealized loss on available-for-sale investments	(85)	(365)	(874)
Foreign currency translation	(6,565)	412	(227)
Comprehensive loss	(183,432)	(228,579)	(89,467)
Less: Comprehensive loss attributable to non-controlling interest	(448)	(4,194)	(1,176)
Comprehensive loss attributable to American Well Corporation	$ (182,984)	$ (224,385)	$ (88,291)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue from Related Parties	$ 12,045	$ 60,839	$ 36,411

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Preferred Stock [Member]Convertible Preferred Stock [Member]	Preferred Stock [Member]Convertible Preferred Stock [Member]Aligned Tele-health Inc. [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2018	$ (204,410)	$ 575,713		$ 414		$ 37,127	$ 1,351	$ (270,737)	$ (231,845)	$ 27,435
Beginning balance (in shares) at Dec. 31, 2018		12,927,549		41,393,622
Issuance of convertible preferred stock, net of issuance costs		$ 45,836	$ 34,250
Issuance of convertible preferred stock, net of issuance costs, Shares		628,719	456,667
Exercise of common stock options	1,034			$ 7		1,027			1,034
Exercise of common stock options, Shares				651,120
Vesting of restricted stock units	2			$ 2					2
Vesting of restricted stock units, Shares				293,937
Stock-based compensation expense	12,135					12,135			12,135
Treasury stock	(158)				$ (158)				(158)
Treasury stock, Shares				(35,834)
Currency translation adjustment	(227)						(227)		(227)
Unrealized loss on available-for-sale securities, net of tax	(874)						(874)		(874)
Net loss	(88,366)							(87,190)	(87,190)	(1,176)
Ending balance at Dec. 31, 2019	(280,864)	$ 655,799		$ 423	(158)	50,289	250	(357,927)	(307,123)	26,259
Ending balance, Shares at Dec. 31, 2019		14,012,935		42,302,845
Issuance of convertible preferred stock, net of issuance costs		$ 146,014
Issuance of convertible preferred stock, net of issuance costs, Shares		1,512,750
Exercise of common stock options	5,912			$ 23		5,889			5,912
Exercise of common stock options, Shares				2,296,899
Vesting of restricted stock units				$ 50		(50)
Vesting of restricted stock units, Shares				5,008,080
Stock-based compensation expense	118,358					118,358			118,358
Treasury stock	(163)				(163)				(163)
Treasury stock, Shares				(61,600)
Retirement of treasury stock					158	(158)
Shares withheld related to net share settlement	(37,405)			$ (18)	(37,405)	18			(37,405)
Shares withheld related to net share settlement, Shares				(1,805,073)
Conversion of Series A, Series B, and Series C convertible preferred stock	801,813	$ (801,813)		$ 1,366		800,447			801,813
Conversion of Series A, Series B, and Series C convertible preferred stock, Shares		(15,525,685)		136,625,900
Issuance of common stock in connection with initial public offering, net of offering costs and underwriting discounts of $54,242	768,025			$ 457		767,568			768,025
Issuance of common stock in connection with initial public offering, net of offering costs and underwriting discounts of $54,242, Shares				45,681,499
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900	99,100			$ 56		99,044			99,100
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900, Shares				5,555,555
Currency translation adjustment	412						412		412
Unrealized loss on available-for-sale securities, net of tax	(365)						(365)		(365)
Net loss	(228,626)							(224,432)	(224,432)	(4,194)
Ending balance at Dec. 31, 2020	1,246,197			$ 2,357	(37,568)	1,841,405	297	(582,359)	1,224,132	22,065
Ending balance, Shares at Dec. 31, 2020				235,604,105
Exercise of common stock options	20,880			$ 66		20,814			20,880
Exercise of common stock options, Shares				6,695,258
Vesting of restricted stock units				$ 75		(75)
Vesting of restricted stock units, Shares				7,394,144
Shares withheld related to net share settlement and retired treasury stock in 2021	(15,038)			$ (8)		8		(15,038)	(15,038)
Shares withheld related to net share settlement and retired treasury stock, Shares				(798,933)
Issuance of stock under employee stock purchase plan	1,599			$ 2		1,597			1,599
Issuance of stock under employee stock purchase plan, Shares				178,021
Issuance of common stock in acquisitions	144,107			$ 128		143,979			144,107
Issuance of common stock in acquisitions, Shares				12,798,992
Stock-based compensation expense	43,809					43,809			43,809
Retirement of treasury stock					$ 37,568	(15)		(37,553)
Capital contributed by selling shareholders of acquired businesses	2,753					2,753			2,753
Currency translation adjustment	(6,565)						(6,565)		(6,565)
Unrealized loss on available-for-sale securities, net of tax	(85)						(85)		(85)
Net loss	(176,782)							(176,334)	(176,334)	(448)
Ending balance at Dec. 31, 2021	$ 1,260,875			$ 2,620		$ 2,054,275	$ (6,353)	$ (811,284)	$ 1,239,258	$ 21,617
Ending balance, Shares at Dec. 31, 2021				261,871,587

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Offering costs and underwriting discounts	$ 54,242
Series C Preferred Stock [Member]
Convertible preferred stock, issuance costs	1,011	$ 1,318
Google Private Placement [Member]
Purchase and issuance costs	$ 900

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (176,782)	$ (228,626)	$ (88,366)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	16,089	10,153	7,761
Provisions for credit losses	714	1,646	717
Amortization of deferred contract acquisition costs	1,971	1,410	1,062
Amortization of deferred contract fulfillment costs	737	852	707
Noncash compensation costs incurred by selling shareholders	2,753
Stock-based compensation expense	43,809	118,358	12,135
Loss on equity method investment	3,132	2,188
Deferred income taxes	(6,245)		(1,388)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(512)	(14,212)	803
Inventories	1,598	(6,024)	(592)
Deferred contract acquisition costs	(2,235)	(2,102)	(1,217)
Prepaid expenses and other current assets	(5,775)	(5,990)	(2,698)
Other assets	117	122	(977)
Accounts payable	5,546	(707)	1,158
Accrued expenses and other current liabilities	(380)	12,887	5,851
Other long-term liabilities	(16,705)	(245)	(699)
Deferred revenue	(9,369)	(2,174)	(16,149)
Net cash used in operating activities	(141,537)	(112,464)	(81,892)
Cash flows from investing activities:
Purchases of property and equipment	(559)	(3,318)	(1,338)
Investment in less than majority owned joint venture	(2,548)	(2,940)
Purchases of investments		(159,608)	(78,946)
Proceeds from sales and maturities of investments	100,000	99,109	246,033
Acquisitions of business, net of cash acquired	(156,526)		(45,750)
Net cash (used in) provided by investing activities	(59,633)	(66,757)	119,999
Cash flows from financing activities:
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs		146,014	45,761
Proceeds from exercise of common stock options	20,806	5,932	1,036
Proceeds from employee stock purchase plan	1,599
Payments for the purchase of treasury stock	(15,038)	(37,568)	(158)
Proceeds from issuance of common stock in initial public offering, net of underwriting costs and commissions		772,931
Proceeds from the issuance of common stock to Google, net of issuance costs		99,100
Payment of deferred offering costs	(1,613)	(3,293)
Net cash provided by financing activities	5,754	983,116	46,639
Effect of exchange rates changes on cash, cash equivalents, and restricted cash	(84)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(195,500)	803,895	84,746
Cash, cash equivalents, and restricted cash at beginning of period	942,711	138,816	54,070
Cash, cash equivalents, and restricted cash at end of period	747,211	942,711	138,816
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	746,416	941,616	137,673
Restricted cash	795	1,095	1,143
Total cash, cash equivalents, and restricted cash at end of period	747,211	942,711	138,816
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1,587	713	193
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in acquisitions	144,107
Receivable related to exercise of common stock options	$ 74
Common stock issuance costs in accrued expenses		$ 1,613
Series C Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Unsettled issuance of Series C preferred stock			75
Aligned Tele-health Inc. [Member] | Series C Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Stock issued			$ 34,250

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading enterprise software company that enables the digital distribution and delivery of care for healthcare’s key stakeholders. The Company’s scalable technology is deployed at the enterprise level of clients, embeds into existing offerings and workflows, spans the continuum of care and enables the delivery of this care across a wide variety of clinical, retail, school and home settings. The Company is subject to a number of risks similar to other companies of a similar size in the high technology industry, including, but not limited to, uncertainty of progress in developing technologies, new technological innovations, dependence on key personnel, protection of proprietary technology, uncertainty of market acceptance of telehealth and the need for additional financing. Acquisitions On August 9, 2021 and August 27, 2021, the Company completed the acquisitions of . See Note 9 “Business Combinations”. Initial Public Offering On September 21, 2020, the Company closed on its initial public offering (the “IPO”) in which the Company issued and sold 45,681,499 shares of Class A common stock, including the exercise of an underwriter option to purchase additional shares, at an issuance price of $18.00 per share. The Company received net proceeds of $767,568 after deducting underwriting discounts and commissions of $49,336 as well as other offering costs of $4,906. Upon the closing of the IPO, the Company’s then-outstanding convertible preferred stock converted into an aggregate of 136,625,900 shares of Class A common stock. Google Private Placement On August 22, 2020, the Company entered into a strategic partnership and stock purchase agreement with Google LLC, where the Company agreed to issue Google $100,000 of Class C common stock, with the price per share to be equal to the purchase price in the IPO. Concurrently with the IPO, the Company consummated the private placement offering to Google and issued Google 5,555,555 shares of Class C common stock for $99,100 after deducting offering costs of $900. Stock Split On August 28, 2020 the Company effected an 8.8-for-1.0 stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s then outstanding convertible preferred stock (see Note 15). The corresponding number of shares and exercise prices related to stock options and RSUs were also adjusted. The impact of the stock split has been applied retrospectively to all periods presented. Liquidity and Capital Resources The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2021, the Company has primarily funded its operations with proceeds from the initial public offering, the sales of convertible preferred stock and revenue from customers who purchase access to the Company’s Platform. On September 21, 2020 the Company closed on the IPO raising $822,267 in gross proceeds. On September 21, 2020 the Company closed on a private placement with Google raising $100,000 in gross proceeds. Since inception, the Company has incurred recurring losses. As of December 31, 2021, the Company had an accumulated deficit of $811,284. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”) (see Note 4) and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 5). Intercompany accounts and transactions have been eliminated in consolidation. For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net income (loss) attributable to noncontrolling interests is recorded in the consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the consolidated balance sheets. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions. Foreign Currency The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2021, the Company’s gains (losses) from foreign currency remeasurement and settlement were $445. During the years ended December 31, 2020 and 2019, the Company’s gains or losses from foreign currency remeasurement and settlements were insignificant. Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of December 31, 2021 and 2020, one customer accounted for 19% and 19% of outstanding accounts receivable, respectively. For the years ended December 31, 2021, 2020 and 2019, sales to one related party customer represented 25%, 22% and 23% of the Company’s total revenue, respectively. Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less at the date of purchase to be cash equivalents. Restricted Cash As of December 31, 2021 and 2020, the Company maintained letters of credit totaling $795 and $1,095, respectively, for the benefit of the landlord of its leased property and performance surety bonds. The Company has classified $0 and $1,095 as current as of December 31, 2021 and 2020, respectively, and $795 and $0 as non-current on its consolidated balance sheet as of December 31, 2021 and 2020, respectively. Investments The Company’s investments are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in total stockholders’ equity (deficit). The Company has classified its available-for-sale investments as current assets on the consolidated balance sheet as these investments generally consist of highly marketable securities that are identified to be available to meet near-term cash requirements. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of interest income and other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company periodically evaluates its investments for other-than-temporary impairment. When assessing investments for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be “other than temporary,” the Company reduces the investment through a charge to the consolidated statement of operations and other comprehensive income (loss). No such adjustments were necessary during the periods presented. As of December 31, 2021 and 2020, there were no investments that had been in a continuous loss position for more than 12 months. Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the consolidated statements of operations and comprehensive loss. Inventories The Company values all of its inventories, which consist primarily of raw material hardware components, at the lower of cost or net realizable value on a first-in, first-out basis (“FIFO”). Write-offs of potentially slow moving or damaged inventory are recorded through specific identification of obsolete or damaged material. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the useful life of the assets. Computer equipment is depreciated over three to four years. Computer software, furniture and fixtures and office equipment are depreciated over three years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Repairs and maintenance costs are expensed as incurred. When assets are sold or retired, the cost and related accumulated depreciation or amortization are removed from the accounts, with any resulting gain or loss recorded in the consolidated statements of operations and comprehensive loss. Business Combinations The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. Transaction costs related to business combinations are expensed as incurred in general and administrative expense in the consolidated statement of operations and comprehensive loss. Determining the fair value of assets acquired and liabilities assumed, and the allocation of the purchase price requires management to use judgment and estimates with regards to the selection of valuation methodologies, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, significant assumptions related to estimates of future revenue and cash flows, expected long-term market growth, expected revenue growth rates, future expected operating expenses, earnings before interest, taxes, depreciation and amortization margin, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, which could last up to one year after the transaction date, all adjustments are recorded in the consolidated statements of operations and comprehensive loss. Goodwill The Company recognizes the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. The Company’s goodwill impairment tests are performed at the enterprise level given the Company’s single reporting unit. The fair value of the reporting unit is estimated using quoted market prices in active markets of the Company’s stock. Declines in market capitalization are assessed to determine whether they would indicate a triggering event. As part of the Step 1 analysis the Company considers assumptions such as control premium, market data and expected future cash flows, as needed. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied the fair value. The Company’s annual goodwill impairment test resulted in no impairment charges in any of the periods in the consolidated financial statements. Intangible Assets Intangible assets acquired in a business combination are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired and reported net of accumulated amortization, separately from goodwill. Finite-lived intangible assets, which primarily consist of customer relationships, contractor relationships, technology and trade name, are stated at historical cost and amortized over the assets’ estimated useful lives. Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets, among others. When testing for asset impairment, the Company groups assets and liabilities at the lowest level for which cash flows are separately identifiable. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than the asset’s carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any impairment losses on long-lived assets. No events or changes in circumstances existed to require an impairment assessment during the years ended December 31, 2021 and 2020. Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. During the year ended December 31, 2020, the Company contributed $2,940 as its initial investment for a 49% interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $11,800 in two phases, which is yet to be defined. In February 2021 the Company made a capital contribution of $2,548 related to a portion of the phase one capital commitment. For the year ended December 31, 2021 and 2020, the Company recognized a loss of $3,132 and $2,188 as its proportionate share of the joint ventures results of operations, respectively. Accordingly, the carrying value of the equity method investment as of December 31, 2021 and 2020 was $168 and $752, respectively. Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense in the consolidated statement of operations and comprehensive loss. For the years ended December 31, 2021, 2020 and 2019, the Company’s advertising expenses were $5,604, $3,860 and $6,107, respectively. Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses include payroll, employee benefits and other expenses associated with product development. Internal-Use Software The Company evaluates development costs incurred in connection with its internal-use software for capitalization. Qualifying costs incurred to develop internal-use software are capitalized when (i) the preliminary project stage is completed, (ii) management has authorized further funding for the completion of the project and (iii) it is probable that the project will be completed and performed as intended. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Capitalized internal-use software development costs are amortized using the straight-line method over an estimated useful life of three years. Such amortization expense for internal-use software is classified as cost of revenues in the consolidated statements of operations and comprehensive loss. Capitalized internal-use software costs were not material to the Company’s consolidated financial statements during the years ended December 31, 2021 and 2020. Stock-Based Compensation The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues stock options and restricted stock units (“RSU’s”) to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. Stock option awards and restricted stock units issued to the co-CEOs prior to the IPO or as a result of the IPO (“IPO RSUs”) were expensed when granted as the requisite future service of the awards is not substantive for accounting purposes. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award’s recipient’s payroll costs are classified. The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company’s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The restricted stock units issued to the co-CEOs as a result of the IPO had the fair value estimated using a binomial lattice approach. The Company historically had been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Deferred Contract Acquisition Costs The Company capitalizes sales commissions and certain parts of the Company bonus that are incremental to the acquisition of customer contracts. These costs are recorded as deferred contract acquisition costs on the consolidated balance sheets. The Company determines whether costs should be deferred based on its sales compensation plans if the commissions are in fact incremental and would not have occurred absent the customer contract. Sales commissions are paid upon the initial acquisition of a contract and are amortized over an estimated period of benefit of five years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The Company determined the period of benefit for commissions paid for the acquisition of initial contracts by taking into consideration the commitment term of the customer contract, the nature of the Company’s technology development life cycle, and an estimated customer relationship period. Amortization of deferred contract acquisition costs is included in sales and marketing expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company reviews these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit of these deferred contract acquisition costs. There were no impairment losses recorded during the periods presented. Deferred Contract Fulfillment Costs The Company capitalizes costs to fulfill contracts with customers in “Prepaid expenses and other current assets” and “Other assets” on its consolidated balance sheet. The Company amortizes these costs to cost of revenue in the consolidated statement of operations and comprehensive loss consistent with the revenue recognition of the performance obligations in the associated contracts. The Company assesses these costs for impairment at the end of each reporting period. There were no impairment losses recorded during the periods presented. Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income, and to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by considering taxable income in carryback years, existing taxable temporary differences, prudent and feasible tax planning strategies and estimating the future taxable profits. The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net Loss per Share The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income or losses for the period had been distributed. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net losses attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends, but contractually does not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued, as their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019. Revenue Recognition Platform subscription The Company generates revenue primarily from contracts with customers who purchase subscriptions to access the Company’s hosted telehealth platform which includes access to the Company’s affiliated medical group. The Company’s customers do not have the right to take possession of the Company’s software operating its telehealth platform at any time. Instead, customers are granted access to the Company’s platform over the contractual period. Access to the platform, including the stand ready obligation to provide access to the affiliated medical group, represents a series of distinct services as the Company continually provides access to and fulfills its obligation to the customer over the contract term. The typical contract term is three years. Most of the Company’s contracts are non-cancelable over the contractual term. Customers typically have the right to terminate their contracts for cause if the Company fails to perform in accordance with the contractual terms. For customers who purchase access to the enterprise telehealth platform (the “Amwell Platform”), the Company hosts a dedicated instance of the Amwell Platform, white-labeled under the customer’s own name, branding, and with customized workflows and operating choices. The implementation services for the Amwell Platform are not distinct within the context of the contract because the Company’s promise to perform the implementation services are not separately identifiable from the access to the Amwell Platform. The implementation services, which customize the customer’s Amwell Platform, are integral to the customer’s ability to derive its intended benefit from the Amwell Platform. The development and implementation services generally span several months and cannot be performed by another entity. Therefore, access to the Amwell Platform and the implementation services are bundled together and represent a single performance obligation. The fixed consideration related to the single performance obligation is generally recognized on a straight-line basis over the contract term beginning on the date access to the Amwell Platform is provided. The Company uses a time-elapsed method to measure progress because the Company transfers control evenly over the contractual period. Customers can also purchase access to the Company’s co-branded telehealth practice hosted on the Company’s shared services platform (the “Amwell Practice”). The implementation services for the Amwell Practice do not significantly modify or customize the Amwell Practice, typically occur over a few days, and can be performed by other entities. Therefore, access to the Amwell Practice and the implementation services are separate outputs promised by the Company and represent two distinct performance obligations. Customers may be billed prior to the related goods or services being transferred to the customer. In determining the transaction price, the Company adjusts the promised amount of consideration for a significant financing component if the timing of payments agreed to by the parties in the contract provide the customer a significant benefit of financing. The Company has applied the practical expedient and recognizes the promised amount of consideration without adjusting for the effects of a significant financing component if the Company expects, at contract inception, that the period between the transfer of goods or services to the customer when the customer pays for that good or service will be one year or less. As of December 31, 2021, the effect of the financing component is not significant and does not materially change the amount of re

Revenue and Deferred Revenue

Revenue and Deferred Revenue	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue and Deferred Revenue	3. Revenue and Deferred Revenue Revenue The following table presents the Company’s revenues disaggregated by revenue source: Years Ended December 31, 2021 2020 2019 Platform subscription $ 108,254 $ 98,361 $ 83,705 Visits 116,617 117,181 40,701 Other 27,918 29,723 24,451 Total Revenue $ 252,789 $ 245,265 $ 148,857 Contract Balances The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the customer. The amount of unbilled receivables as of December 31, 2021 and 2020 is $5,697 and $3,376 and has been included within accounts receivable and as of December 31, 2021 $781 has been included within other assets on the consolidated balance sheet. Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the years ended December 31, 2021, 2020 and 2019, the Company recognized revenue of $56,473, $53,601, and $59,006, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. The Company receives payments from customers based upon contractual billing schedules. The Company typically invoices its customers annually in advance for their annual software access fee. The Company records accounts receivable when the right to consideration becomes unconditional. Payment terms on invoiced amounts are typically net 30 days. Deferred Revenue Significant changes in the Company’s deferred revenue balance for the years ended December 31, 2021, 2020 and 2019: Years Ended December 31, 2021 2020 2019 Total deferred revenue, beginning of the period $ 74,800 $ 77,386 $ 93,299 Additions 123,717 109,542 85,167 Recognized (122,621 ) (112,128 ) (101,080 ) Total deferred revenue, end of the period $ 75,896 $ 74,800 $ 77,386 Current deferred revenue 68,841 66,693 66,490 Non-current deferred revenue 7,055 8,107 10,896 Total $ 75,896 $ 74,800 $ 77,386 Transaction Price Allocated to Remaining Performance Obligations As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was $219,893 and $192,238, respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years. As it pertains to the December 31, 2021 amount, the Company expects to recognize 46%

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable Interest Entities	4. Variable Interest Entities The Company provides services pursuant to contracts with PCs which in turn contracts with physicians to provide telehealth medical services. The PC’s collectively represent the Company’s affiliated medical group. The PCs were designed and structured to comply with the relevant laws and regulations governing professional medical practice, which generally prohibits the practice of medicine by lay persons or entities. To satisfy these regulatory requirements, all of the issued and outstanding equity interests of the PCs are owned by a licensed medical professional nominated by the Company (the “Nominee Shareholder”). Upon formation of the PCs, and initial issuance of equity interests, the Nominee Shareholder contributes a nominal amount of capital in exchange for their interest in the PC. The Company then executes with each PC a Business Support Agreement (“BSA”), which provide for various administrative and management services to be provided by the Company to the PC, and a Stock Transfer Agreement (“STA”), which provide for transition of ownership of the PCs. The Company provides all of the necessary capital for the operations of the PCs through loans to the PCs. The Company also has exclusive responsibility for the provision of all nonmedical services including contracting with customers who access the PCs for a medical visit, handling all financial transactions and day-to-day operations of each PC, overseeing the establishment of telehealth policies and protocol, and making recommendations to the PC in establishing the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the STA provides that the Company’s Board of Directors has the power and authority to change the Nominee Shareholder at any time for any reason, and designate a new Nominee Shareholder who will purchase the equity interests from the predecessor Nominee Shareholder for the same nominal amount, effectively limiting the Nominee Shareholder’s rights to returns of the PC. The Nominee Shareholders, notwithstanding their legal form of ownership of equity interests in the PC, have no substantive profit-sharing rights in the PCs. Based upon the provisions of these agreements, the Company determined that the PCs are variable interest entities due to its equity holder having insufficient capital at risk, and the Company has a variable interest in the PCs. The Company consolidated the PCs under the VIE model since the Company has the power to direct activities that most significantly impact the PCs economic performance and the right to receive benefits or the obligation to absorb losses that could potentially be significant to the PCs. Furthermore, as a direct result of nominal initial equity contributions by the Nominee Shareholder, the financial support the Company provides to the PCs (e.g. loans) and the provisions of the STA, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to the Company’s stockholders. The aggregate carrying value of total assets and total liabilities included on the consolidated balance sheets for the PCs after elimination of intercompany transactions were $29,770 and $1,485, respectively, as of December 31, 2021 and $22,682 and $1,998, respectively as of December 31, 2020. Total revenue included on the consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $72,125, $78,396 and $23,450 for the years ended December 31, 2021, 2020 and 2019, respectively. Net loss included on the consolidated statements of operations and comprehensive was not material for the years ended December 31, 2021, 2020 and 2019.

National Telehealth Network

National Telehealth Network	12 Months Ended
	Dec. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]
National Telehealth Network	5. National Telehealth Network In 2012, the Company and an affiliate of Anthem, Inc. formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significance influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50%. The Company also obtained the right to elect the Chairman of NTN who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s consolidated financial statements. However, because the Company owns less than 100% of NTN, the Company recognizes net income (loss) attributable to non-controlling interest in the consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party. The proportionate share of the loss attributed to the non-controlling interest amounted to $448, $4,194 and $1,176 for the years ended December 31, 2021, 2020 and 2019, respectively. The carrying value of the non-controlling interest was $21,617, $22,065 and 26,259 as of December 31, 2021, 2020 and 2019.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: December 31, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 671,107 $ — $ — $ 671,107 Investments — — — — Total financial assets: Contingent consideration — — 16,450 16,450 Total financial liabilities: $ 671,107 $ — $ 16,450 $ 687,557 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 892,934 $ — $ — $ 892,934 Investments — 99,963 — 99,963 $ 892,934 $ 99,963 $ — $ 992,897 As of December 31, 2021 and 2020, the Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. As of December 31, 2020, the Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. During the years ended December 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3. The Company has classified its net liability for contingent earnout considerations relating to the August 2021 Acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included the Monte Carlo method that uses key assumptions to model future revenue and costs of goods sold projections. A description of the August 2021 Acquisitions is included within Note 9. revenue and the revenue discount rate of 3.1% and 1.3% for SilverCloud and Conversa, respectively, The contingent earnout payments for each acquisition are based on the achievement of certain revenue Year Ended December 31, 2021 Beginning Balance as of January 1 $ — Initial estimate of fair value related to SilverCloud contingent consideration 29,360 Initial estimate of fair value related to Conversa contingent consideration 15,230 Accretion of contingent consideration 600 Fair value adjustment (13,740 ) Earned amount due to shareholders (15,000 ) Ending Balance $ 16,450

Investments

Investments	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Investments	7. Investments As of December 31, 2021 and 2020, the fair value of the Company’s investments by type of security was as follows: December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ — December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ 99,854 $ 109 $ — $ 99,963 99,854 109 — 99,963

Allowance for Credit Losses

Allowance for Credit Losses	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Allowance for Credit Losses	8. Allowance for Credit Losses Changes in the allowance for credit losses were as follows: Years Ended December 31, 2021 2020 2019 Allowance for credit losses, beginning of the period $ 1,556 $ 686 $ 396 Provisions 714 1,646 717 Write-offs (461 ) (776 ) (427 ) Allowance for credit losses, end of the period $ 1,809 $ 1,556 $ 686

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Business Combinations	9. Business Combinations Aligned Telehealth, Inc. In November 2019, the Company acquired all the issued and outstanding shares of Aligned Telehealth, Inc. (“Aligned”). This acquisition will combine Aligned’s customer base with the Amwell Platform to increase the number of hospitals and health plans utilizing telehealth. The aggregate consideration paid was $82,948, which consists of (i) 456,667 shares of the Company’s Series C convertible preferred stock valued at $34,250; (ii) $48,688 of cash and (iii) contingent consideration of $10. The Company was obligated to pay an earn-out up to $70,000 contingent upon Aligned achieving certain revenue and margin thresholds for the year ended December 31, 2020. The Company estimated the fair value of the contingent consideration as of the acquisition date. The contingent consideration was subject to remeasurement at each reporting date until December 31, 2020. The earn-out was not achieved as of December 31, 2020, with the remeasurement adjustment of $10 was recorded in the consolidated statements of operations and comprehensive loss. The acquisition was a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $1,494 and recognized as general and administrative expense in its consolidated statements of operations and comprehensive loss during the year ended December 31, 2019. The results of operations of Aligned have been included in the Company’s consolidated statements of operations from the acquisition date. Actual revenue and losses of Aligned since the acquisition date as well as pro forma combined results of operations for the Aligned acquisition have not been presented because the effect of the acquisition was not material to the Company’s consolidated financial results for the periods presented. The fair value of the contingent consideration was reduced to $ 0 during the year ended December 31, 2020. The final allocation of the purchase consideration of $82,948 is as follows: Aligned Cash $ 2,938 Accounts receivable 3,612 Identifiable intangible assets 14,100 Other assets 179 Total assets acquired 20,829 Current liabilities (3,102 ) Deferred tax liability (1,388 ) Total liabilities assumed (4,490 ) Goodwill 66,609 Total purchase consideration $ 82,948 The following are the identifiable intangible assets acquired and their respective weighted average useful lives, as determined based on final valuations: Aligned Weighted Average Life (Years) Customer relationships $ 13,800 7.0 Trade name 300 7.0 Total $ 14,100 Customer-relationship intangible assets were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. Key assumptions used in developing the valuation included the estimated annual net cash flows (including forecasted revenue, gross margin, and expenses) and the discount rate that appropriately reflects the risk inherent in each future cash flow stream, all of which were estimated by management. Goodwill represents the excess of the purchase consideration over the estimated acquisition date fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill is primarily attributable to expected post-acquisition cross-selling opportunities from integrating Aligned’s customer relationships with the Amwell Platform. SilverCloud and Conversa On August 27, 2021, the Company completed the acquisition of SilverCloud through a merger in which SilverCloud became a wholly-owned subsidiary of the Company. The cash consideration paid was $105,195 net of cash acquired of $12,239. The stock consideration was comprised of 8.1 million shares of the Company’s Class A common stock valued at $85,571, and escrow share consideration of $6,376. SilverCloud is a leading digital mental health platform. The Company is obligated to pay an earn-out of up to $40,000 contingent upon SilverCloud achieving certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $29,360. The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $4,854 which included transaction costs from financial and legal advisors and other transaction related fees, as well as $717 of noncash compensation costs, and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses. The noncash compensation costs related to the SilverCloud acquisition are for additional noncash compensation costs incurred by the selling SilverCloud shareholders for certain employees that have continued employment after the transaction date and through the earn-out period, and will be a reoccurring cost until the payout of earn-out in 2023 . On August 9, 2021, the Company completed the acquisition of Conversa through a merger in which Conversa became a wholly-owned subsidiary of the Company. The cash consideration paid was $51,331 net of cash acquired of $9,735. The stock consideration was comprised of 4.7 million shares of the Company’s Class A common stock valued at $52,160. Conversa is a leader in automated virtual healthcare. The Company is obligated to pay an earn-out of up to $30,000 contingent upon Conversa achieving certain integration thresholds in the first quarter of 2022, and certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $15,230. The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $2,435 which included transaction costs from financial and legal advisors and other transaction related fees and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses. The August 2021 August 2021 August 2021 August 2021 August 2021 The following table summarizes the preliminary fair value estimates of the assets acquired and liabilities assumed for the SilverCloud and Conversa acquisitions at the respective acquisition dates. The Company, with the assistance of a third-party valuation expert, estimated the preliminary fair value of the acquired tangible and intangible assets with significant estimates such as revenue projections. In the fourth quarter of 2021, the Company recorded a $2,825 increase and a $1,268 decrease to goodwill related to the assessment of the tax attributes of the business combinations for SilverCloud and Conversa, respectively. In addition, the Company recorded a $9 and $66 decrease to goodwill with the finalization of the net working capital adjustment for SilverCloud and Conversa, respectively. The allocation of the consideration transferred to the assets acquired and the liabilities assumed for the August 2021 Acquisitions remains preliminary and therefore can be revised as a result of additional information obtained due to completing the final assessment of the tax attributes of the business combinations. Additional adjustments may be recorded within the measurement period, which will not exceed one year from the acquisition date. Identifiable assets acquired and liabilities assumed (in thousands): SilverCloud Conversa Health Purchase consideration: Cash consideration, net of cash acquired $ 105,195 $ 51,331 Stock consideration 85,571 52,160 Contingent consideration 29,360 15,230 Escrow share consideration 6,376 Working capital adjustment (300 ) (127 ) Total consideration transferred $ 226,202 $ 118,594 Allocation of Consideration transferred: Accounts receivable $ 2,630 $ 3,651 Identifiable intangible assets 78,146 34,700 Other assets 491 4,604 Total assets acquired 81,267 42,955 Current liabilities 2,155 8,463 Deferred revenue 5,813 4,655 Other long-term liabilities 11,557 115 Total liabilities assumed 19,525 13,233 Goodwill $ 164,460 $ 88,872 $ 226,202 $ 118,594 The amount allocated to goodwill reflects the benefits the Company expects to realize from post-acquisition cross selling opportunities from integrating customer relationships and from the growth of the respective acquisitions’ operations. The following are the identifiable intangible assets acquired in the August 2021 SilverCloud Weighted Average Life (Years) Conversa Health Weighted Average Life (Years) Technology $ 34,996 5.0 $ 20,400 5.0 Tradename 10,800 7.0 4,200 5.0 Customer relationships 32,350 10.0 10,100 10.0 Total $ 78,146 $ 34,700

Deferred Contract Acquisition a

Deferred Contract Acquisition and Contract Fulfillment Costs	12 Months Ended
	Dec. 31, 2021
Contract With Customer Asset And Liability [Abstract]
Deferred Contract Acquisition and Contract Fulfillment Costs	10. Deferred Contract Acquisition and Contract Fulfillment Costs The following table represents a rollforward of the Company’s deferred contract acquisition costs: December 31, 2021 2020 Beginning balance as of January 1 $ 3,461 $ 2,769 Additions to deferred contract acquisition costs 2,235 2,102 Amortization of deferred contract acquisition costs (1,971 ) (1,410 ) Ending balance $ 3,725 $ 3,461 Deferred contract acquisition costs, current $ 1,697 $ 2,134 Deferred contract acquisition costs, noncurrent 2,028 1,327 Total $ 3,725 $ 3,461 Amortization expense related to deferred contract acquisition costs for the years ended December 31, 2021, 2020 and 2019 was $1,971, $1,410 and $1,062, respectively. The following table represents a rollforward of the Company’s deferred contract fulfillment costs: December 31, 2021 2020 Beginning balance as of January 1 $ 1,861 $ 2,086 Additions to deferred contract fulfillment costs 266 627 Amortization of deferred contract fulfillment costs (737 ) (852 ) Ending balance $ 1,390 $ 1,861 Deferred contract fulfillment costs, current $ 736 $ 624 Deferred contract fulfillment costs, noncurrent 654 1,237 Total $ 1,390 $ 1,861 Amortization expense related to deferred contract fulfillment costs for the years ended December 31, 2021, 2020 and 2019 was $737, $852 and $707, respectively.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	11. Property and Equipment, Net Property and equipment, net consisted of the following: As of December 31, 2021 2020 Furniture and fixtures $ 231 $ 930 Computer and office equipment 7,965 7,638 Computer software 5,086 4,847 Leasehold improvements 692 2,162 13,974 15,577 Less: Accumulated depreciation and amortization (11,739 ) (11,741 ) Property and equipment, net $ 2,235 $ 3,836 Depreciation and amortization expense related to property and equipment was $2,160, $2,146 and $1,769 for the years ended December 31, 2021, 2020 and 2019, respectively. During the year ended December 31, 2021 the Company disposed of fully depreciated assets with a gross value of $1,851.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	12. Goodwill and Intangible Assets Goodwill consisted of the following as of: December 31, 2021 2020 Beginning Balance as of January 1 $ 193,877 $ 193,877 Goodwill acquired 253,332 Currency translation adjustments (4,448 ) — Ending Balance $ 442,761 $ 193,877 Identified intangible assets consisted of the following as of: Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2021 Customer relationships $ 81,053 $ (16,842 ) $ 64,211 8.2 Contractor relationships 535 (247 ) 288 7.0 Trade name 14,435 (706 ) 13,729 5.8 Technology 90,464 (16,283 ) 74,181 5.0 $ 186,487 $ (34,078 ) $ 152,409 Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2020 Customer relationships $ 38,782 $ (11,380 ) $ 27,402 7.0 Contractor relationships 535 (206 ) 329 8.0 Trade name 300 (300 ) — — Technology 37,063 (9,266 ) 27,797 7.5 $ 76,680 $ (21,152 ) $ 55,528 Amortization expense related to intangible assets for the years ended December 31, 2021, 2020 and 2019 was $13,929, $8,007 and $5,992, respectively. Included in amortization expense for the year ended December 31, 2020 was $255 related to the write off of the remaining Trade name for Aligned. Estimated future amortization expense of the identified intangible assets as of December 31, 2021, is as follows: 2022 $ 25,039 2023 25,039 2024 25,055 2025 25,039 2026 20,617 Thereafter 31,620 152,409

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued Expenses	13. Accrued Expenses Accrued expenses consist of the following: As of December 31, 2021 2020 Employee compensation and benefits $ 21,572 $ 20,521 Professional services 8,766 6,832 Earned contingent consideration 15,000 — Provider services 5,473 4,632 Other 7,900 10,150 Total $ 58,711 $ 42,135

Line of Credit

Line of Credit	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Line of Credit	14. Line of Credit In January 2011, the Company entered into a credit agreement (the “Line of Credit”) with a financial institution that provides for maximum borrowings in one or more advances of an amount up to $5,000. Borrowings under the Line of Credit accrue interest at the London Interbank Offered Rate plus 1.25%. Borrowings are repayable immediately upon demand by the financial institution. In November 2017, the Line of Credit was amended to increase the maximum borrowings to $7,000. As of December 31, 2020, the Company had no outstanding borrowings under the Line of Credit. The Line of Credit arrangement expired during the year ended December 31, 2021.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders Equity Note [Abstract]
Stockholders' Equity	15. Stockholders’ Equity Convertible Preferred Stock The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Authorized Shares Issued Shares Outstanding Liquidation Preference Carrying Value Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799 In the year ended December 31, 2019, the Company issued and sold 628,719 shares of Series C preferred stock at a price of $75 per share for gross proceeds of $47,154. The Company incurred $1,318 of issuance costs in connection with the issuance of the Series C preferred stock. Additionally, the Company issued 456,667 shares of Series C preferred stock at a price of $75 per share in connection with the acquisition of Aligned (see Note 9). In February 2020, the Company issued and sold 170,000 shares of Series C preferred stock at a price of $75 per share for gross proceeds of $12,750. The Company incurred $261 of issuance costs in connection with the issuance of the Series C preferred stock In May 2020, the Company issued and sold 1,342,750 shares of Series C preferred stock at a price of $ 100 per share for gross proceeds of $ 134,275 . The Company incurred $ 750 of issuance costs in connection with the issuance of the Series C preferred stock. In conjunction with the Company’s IPO in September 2020, all shares of convertible preferred stock then outstanding, totaling 15,525,685 shares (pre-split), were automatically converted into an equivalent number of shares of Class A common stock on an 8.8-to-1.0 basis pursuant to a stock split and their carrying value, totaling $801,813 was reclassified into stockholders’ equity on the consolidated balance sheet. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. Prior to the conversion of the convertible preferred stock in September 2020, the stockholders of convertible preferred stock had the following rights and preferences: Voting Rights The holders of Preferred Stock are entitled to the number of votes equal to the number of shares of common stock into which such shares of Preferred Stock could convert on the record date for the determination of stockholders entitled to vote. In addition, the holders of the Preferred Stock, voting as a single class, and on an as converted to common stock basis, are entitled to elect one director of the Company. The holders of Preferred Stock, voting as a single class, and on an as converted to common stock basis, and the holders of common stock, voting as a separate class, are entitled to elect three directors of the Company. The holders of the common stock, voting as a separate class, are entitled to elect the remaining directors of the Company. Dividends The holders of the Preferred Stock are entitled to receive noncumulative dividends when, as and if declared by the board of directors. In addition, the holders of shares of Preferred Stock are entitled to participate pro rata on an as-converted-basis on any dividends paid to the holders of common stock. The holders of the Series B preferred stock and Series C preferred stock, collectively (the “Senior Preferred Stock”) are entitled to participate pro rata (calculated as if such Senior Preferred stock and Series A preferred stock had converted to common stock) on any dividends paid to the holders of Series A preferred stock. No dividends have been declared through December 31, 2020. Liquidation In the event of a liquidation, voluntary or involuntary, dissolution or winding up of the Company or Deemed Liquidation Event (as defined below), the holders of the Senior Preferred Stock will be entitled to receive, on a pari passu After payments have been made in full to the holders of Senior Preferred Stock, then, to the extent available, the remaining assets of the Company available for distribution to its stockholders will be distributed among the holders of Series A preferred stock. The holders of the Series A preferred stock will be entitled to receive (i) an amount per share equal to the applicable Original Issue Price plus (ii) any dividends declared but unpaid plus (iii) a non-compounding five percent per annum dividend on the Original Issue Price for each share of Series A preferred stock from the date of original issuance. In the event that proceeds are not sufficient to permit payment in full to the holders of the Series A preferred stock, the proceeds will be ratably distributed among the holders of the Series A preferred stock. After payments have been made in full to the holders of the Senior Preferred Stock and Series A preferred stock, then to the extent available, the holders of common stock are entitled to share ratably in the remaining assets of the Company. Unless the holders of a majority of the Preferred Stock, voting together as a single class, on an as-converted to common stock basis, elect otherwise, a Deemed Liquidation Event includes a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company. Conversion Each share of Preferred Stock is convertible, at the option of the holder, at any time, or will automatically be converted into shares of common stock at the applicable conversion ratio then in effect (i) upon closing of a qualifying IPO at a price per share to the public of at least $6.82, subject to appropriate adjustments (described below), and with aggregate gross proceeds of at least $25,000 or (ii) upon the vote or written consent of the holders of a majority of the outstanding shares of Preferred Stock, voting together as a single class and on an as-converted to common stock basis. The conversion ratio of each series of preferred stock is determined by dividing the Original Issuance Price of each series by the applicable Conversion Price of each series. The Original Issue Price per share is $10.00 for Series A preferred stock, $30.00 for Series B preferred stock and $45.00 for Series C preferred stock, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock. The Conversion Price is $1.14 for Series A, $3.41 for Series B and $5.11 for Series C preferred stock. The Conversion Price is subject to appropriate adjustment in the event of any deemed issuance of additional shares, stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in the Company’s certificate of incorporation, as amended and restated. Each outstanding share of Preferred Stock was convertible into common stock on a 8.8-for-one Undesignated Preferred Stock In connection with our IPO in September 2020, we filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.01 per share, with rights and preferences, including voting rights, designated from time to time by our board of directors. No shares of preferred stock were issued or outstanding as of December 31, 2021. Common Stock In September 2020, upon completion of the IPO, the Company sold 45,681,499 shares of Class A common stock at an offering price of $18.00 per share, including 4,459,277 shares of Class A common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. The Company received net proceeds of $767,568, after deducting underwriting discounts and commissions of $49,336 and offering costs of approximately $4,906. In September 2020, the Company sold 5,555,555 shares of Class C common stock in connection with the stock purchase agreement with Google, LLC for net proceeds of $99,100, after deducting offering costs of $900. Concurrently with the IPO, the Company used $24,157 of the proceeds from the IPO to repurchase 1,340,354 shares of Class A and Class B common stock from certain executive officers and other employees, to permit such executive officers and other employees to pay taxes owed in connection with the vesting of equity awards, including the repayment of third party loans incurred to finance the payment of such taxes. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes capital stock of 1,000,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 200,000,000 shares of Class C common stock, par value $0.01 per share. Except for the rights noted below, each Class A, Class B and Class C common stock have the same rights, are equal in all respects and are treated by us as one class of shares. Each share of Class A and Class C common stock is entitled to one vote per share on all matters presented for a vote, except that Class C common stock does not have the right to vote for elections of directors. Subject to certain conditions, Class B common stock is collectively entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power), and each share of Class B common stock will be entitled to a number of votes equal to the total number of votes held by all Class B common stock divided by the total number of then outstanding shares of Class B common stock. Shares of Class B and Class C common stock will be converted into shares of Class A common stock on a one-for-one basis upon the occurrence of certain events. Shares of Class B common stock will automatically convert on the first business day (i) after the date on which the outstanding shares of Class B common stock constitutes less than 5% of the aggregate number of shares of common stock then outstanding, (ii) after the date on which neither founder is serving as an executive officer or (iii) following seven years after the date the amended and restate certificate of incorporation becomes effective, provided that, such period may, to the extent permitted by law and applicable stock exchange rules, be extended for three years upon the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of Class A common stock entitled to vote thereon, voting separately as a class. Shares of Class C common stock will be convertible at the option of the holder upon determination that a Hart-Scott-Rodino Antitrust Improvements Act (“HSR”) filing is not necessary prior to the holder’s conversion of such shares or, if required, upon expiration or termination of the HSR waiting period. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend right of the preferred stockholders. No dividends have been declared through December 31, 2021. In August 2021, the Company issued 4.7 million and 8.1 million shares of Class A common stock at a fair value of $11.20 and $10.51 per share in connection with the acquisitions of Conversa and SilverCloud, respectively (see Note 9). In the year ended December 31, 2021 4,079,035 shares of Class B common stock were converted to Class A common stock. As of December 31, 2021 the par value of the Class A, Class B and Class C shares was $2,294, $270 and $56, respectively. Shares Authorized Shares Issued Shares Outstanding Class A 1,000,000,000 229,402,453 229,402,453 Class B 100,000,000 26,913,579 26,913,579 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 261,871,587 261,871,587 As of December 31, 2021and 2020, the Company had reserved 61,989,749 and 61,392,747 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units and the number of shares remaining available for future grant, respectively. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. The 2020 Plan is administered by the board of directors with respect to awards to non-employee directors and by the compensation committee, with respect to other participants, are collectively, referred to as the plan administrator. The exercise prices, vesting and other restrictions are determined at the discretion of the plan administrator. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Stock options granted under the Plan typically vest over four years and expire ten years after the grant date. The Company had 31,470,984 shares available for grant as of December 31, 2021. Activity under the Plans is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2021 23,167,514 $ 4.37 6.2 $ 487,758 Granted — $ — Forfeited (578,503 ) $ 5.82 Expired — $ — Exercised (6,695,256 ) $ 3.21 Outstanding as of December 31, 2021 15,893,755 $ 4.81 5.9 $ 23,876 Vested and expected to vest as of December 31, 2021 15,395,398 $ 4.61 5.8 $ 23,752 Options exercisable as of December 31, 2021 13,407,882 $ 4.38 5.5 $ 23,120 The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021, 2020 and 2019, was $106,407, $31,194 and $2,433, respectively. The aggregate intrinsic value of common stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The weighted-average grant date fair value of common stock options granted during the years ended December 31, 2021, 2020 and 2019, was $0, $4.17 and $2.81, respectively. The Company received cash proceeds from the exercise of common stock options of $20,806, $5,932 and $1,036 during the years ended December 31, 2021, 2020 and 2019, respectively. The weighted average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Years Ended December 31, 2021 2020 2019 Risk-free interest rate N/A 1.09 % 2.17 % Expected term (in years) N/A 6.1 6.0 Expected volatility N/A 52 % 50 % Expected dividend yield N/A 0 % 0 % Executive Equity Awards Each CEO has received restricted stock units, equaling up to 1.5% of the Company’s fully-diluted outstanding capital stock as a result of the IPO (“IPO RSUs”), 50% of the IPO RSUs (representing 0.75% of the Company’s fully diluted outstanding capital stock immediately prior to the IPO or 3,230,750 shares of Class A common stock) were granted on the closing date of the IPO based on the closing price per share on the IPO closing date, and 50% (representing up to 0.75% of the Company’s fully diluted outstanding capital stock immediately prior to the IPO or 3,230,750 shares of Class A common stock) was granted on the 180-day anniversary of the IPO, based on a specific range of the price per share of the Company’s publicly traded common stock prior March 16, 2021, and will vest over a three-year period, with one-third vesting on the first anniversary of the IPO’s closing date and the remaining vesting in equal quarterly installments thereafter. As the issuance of the second 50% tranche is based upon events that are probable the expense related to both tranches of the IPO RSUs was recognized in the three months ended September 30, 2020. The grant-date fair value of each of the awards issued on the IPO closing date and to be issued on the 180-day anniversary of the IPO were estimated using a binomial lattice approach. The main inputs to valuing the IPO RSUs include the fair value of Class A common stock ($9.96 post-split), expected volatility (60%) and the expected date of the IPO (September 30, 2020). The Company recognized a total of $23,644 in stock-based compensation expense, which included both tranches of the IPO RSUs for each CEO, on the date of the IPO as the requisite future service of the awards is not substantive for accounting purposes. Restricted Stock Units The following table summarizes the unvested restricted stock unit activity for the year ended December 31, 2021: Shares Weighted Average Grant Date Fair Value Unvested as of January 1, 2021 11,014,450 $ 14.43 Granted 9,011,024 16.93 Vested (7,394,144 ) 9.34 Forfeited (912,517 ) 13.62 Unvested as of December 31, 2021 11,718,813 $ 19.63 The total grant date fair value of RSU’s granted for the years ended December 31, 2021, 2020 and 2019 was $152,550, $195,655 and $15,135, respectively. The aggregate intrinsic value of restricted stock units vested for the years ended December 31, 2021, 2020 and 2019 was $90,726, $73,836 and $1,693, respectively. 2020 Employee Stock Purchase Plan In July and August 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Employee Stock Purchase Plan (“ESPP”). A total of 3,084,218 shares of Class A common stock were reserved for issuance under the ESPP. The ESPP became effective March 1, 2021. Rights granted under the ESPP will be issued only with respect to shares of Class A common stock. The purchase price of the shares will not be less than 85% of the fair market value of Class A common stock on the lower of the purchase date, which will be the final trading day of the purchase period, or the enrollment date, which will be the first trading day of the offering period. During the year ended December 31, 2021, the Company issued 178,021 shares under the ESPP. As of December 31, 2021 2,906,197 shares remained available for issuance. Stock-Based Compensation Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows: Years Ended December 31, 2021 2020 2019 Cost of revenues $ 1,655 $ 1,087 $ 536 Research and development 7,613 4,793 1,477 Selling and marketing 7,666 4,147 2,418 General and administrative 26,875 108,331 7,704 Total $ 43,809 $ 118,358 $ 12,135 As of December 31, 2021, total unrecognized compensation cost related to the unvested common stock-based awards was $80,121, which is expected to be recognized over a weighted-average period of 2.9 years.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	16. Leases The Company’s primary lease represents the lease for its corporate headquarters in Boston, Massachusetts. The Company modified the corporate headquarter lease during the third quarter of 2021. Rent expense for the year ended December 31, 2021 was $5,870. The carrying value of the Company’s right-of-use assets are substantially concentrated in real estate as the Company primarily leases office space. The Company’s policy is not to record leases with an original lease term of one year or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. The Company does not have any lease contracts with the option to purchase as of December 31, 2021. Years Ended December 31, 2021 2020 2019 The components of lease cost under ASC 842 were as follows: Operating lease cost $ 5,617 $ 6,632 $ 6,649 Short-term lease cost — — — Variable lease cost — — — Total lease cost $ 5,617 $ 6,632 $ 6,649 Years Ended December 31, 2021 2020 2019 Supplemental cash flow information: Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 6,352 $ 7,006 $ 6,480 Non-cash lease activity: Right-of-use lease assets obtained in exchange for new operating lease liability: Operating leases $ 15,506 $ 417 $ 355 As of December 31, 2021 2020 Supplemental balance sheet information related to leases is as follows: Operating leases Operating lease right-of-use assets $ 16,422 $ 6,609 Total operating right-of-use lease assets $ 16,422 $ 6,609 Operating lease liabilities, current 1,918 6,357 Operating lease liabilities, net of current portion 14,694 1,296 Total operating lease liabilities $ 16,612 $ 7,653 Weighted-average remaining lease term (in years) 5.0 years 1.3 years Weighted-average discount rate 1.1 % 2.9 % As of December 31, 2021, minimum future lease payments for these operating leases were as follows: Years ending December 31, 2022 $ 2,100 2023 3,683 2024 3,416 2025 3,484 2026 3,554 Thereafter 893 Total lease payments $ 17,130 Less imputed interest (518 ) Total present value of lease liabilities $ 16,612 Indemnification The Company’s arrangements generally include certain provisions for indemnifying customers against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies customers against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the customer. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through December 31, 2021, there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. On September 14, 2020, the Company received a letter from Teladoc Health, Inc. alleging that certain of the Company’s cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc Health, Inc filed a claim against the Company related to these allegations. The Company believes that these claims lack merit and intends to defend against them vigorously.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes During the years ended December 31, 2021, 2020 and 2019 the Company recorded an income tax (benefit) expense of For the years ended December 31, 2021, 2020 and 2019, the Company’s loss before income taxes is primarily generated in the United States as the pre-tax loss from the Company’s foreign subsidiaries is not significant. The components of our current and deferred portions of the provision for income taxes are presented in the table below: Years Ended December 31, 2021 2020 2019 Current income tax provision (benefit): Federal $ — $ — $ — State 41 97 34 Foreign 828 448 285 Total Current $ 869 $ 545 $ 319 Deferred income tax provision (benefit): Federal $ (5,730 ) $ 103 $ (821 ) State 1 21 (252 ) Foreign (516 ) (30 ) (49 ) Total Deferred $ (6,245 ) $ 94 $ (1,122 ) Total provision (benefit) for income taxes $ (5,376 ) $ 639 $ (803 ) The following reconciles the differences between income taxes computed at the federal statutory rate and the provision for income taxes: Years Ended December 31, 2021 2020 2019 Federal statutory income tax rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 4.5 2.0 3.0 Valuation allowance (24.5 ) (13.3 ) (21.3 ) Stock-based compensation 1.9 (9.5 ) (1.1 ) Other 0.1 (0.5 ) (0.7 ) Effective income tax rate 3.0 % (0.3 %) 0.9 % Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 179,555 $ 116,965 Research and development credit carryforwards 1,676 2,081 Deferred revenue 2,863 4,848 Deferred compensation 7,176 7,142 Startup costs 84 171 Leasing obligation 4,115 1,937 Other 904 1,030 Total deferred tax assets 196,373 134,174 Total valuation allowance (164,391 ) (118,795 ) Total net deferred tax assets 31,982 15,379 Joint venture investment basis difference (1,453 ) (1,706 ) Intangibles (30,265 ) (10,563 ) Right-of-use assets (4,068 ) (1,669 ) Other (1,131 ) (1,374 ) Total deferred tax assets (liabilities) (36,917 ) (15,312 ) Net deferred tax liabilities $ (4,935 ) $ 67 The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company's history of cumulative net losses incurred in the U.S. since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net domestic deferred tax assets as of December 31, 2021, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period. Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increase in net operating loss carryforwards in 2021, 2020 and 2019 and were as follows: Years Ended December 31, 2021 2020 2019 Valuation allowance as of beginning of the year $ 118,795 $ 88,499 $ 69,433 Increases recorded to income tax provision 51,348 30,296 20,454 Decreases recorded as a benefit to income tax provision (5,752 ) — (1,388 ) Valuation allowance as of end of year $ 164,391 $ 118,795 $ 88,499 As of December 31, 2021, the Company has federal net operating loss carryforwards of approximately $703,416, which begin to expire in 2026. The Company’s federal net operating losses generated for the years ended after December 31, 2017, which amounted to a total of $472,047, can be carried forward indefinitely. The Company has tax effected state net operating losses of approximately $30,050, which began to expire in 2022. In addition, the Company has federal and state and research and development tax credit carryforwards of $1,602 and $200, which begin to expire in 2027 and 2027, respectively. Utilization of the Company's net operating loss ("NOL") carryforwards and research and development ("R&D") credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 ("Section 382") as well as similar state provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. Since its formation, the Company has raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders' subsequent disposition of those shares, could result in a change of control as defined by Section 382. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict its ability to utilize its NOL and R&D credit carryforwards. As a result of this analysis, the Company does not believe there are any significant limitations on its ability to utilize these carryforwards generated through December 31, 2021 . However, changes in ownership occurring after December 31, 2021 , could affect the limitation in future years, and any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. The Company does not have unrecognized tax benefits related to uncertain tax positions. The Company recognizes both accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception. The tax years 2006 through 2021 remain open to examination by major taxing jurisdictions to which the Company is subject, which is primarily in the United States (U.S.), as carryforward attributes generated in prior years may still be adjusted upon examination by the Internal Revenue Service (IRS) or state tax authorities if they have or will be used in a future period. The Company files income tax returns in the U.S. federal and various state jurisdictions. There are currently no federal or state audits in progress by the IRS or any other jurisdictions for any tax years.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	18. Related-Party Transactions Teva Pharmaceuticals, Industries Ltd Teva Pharmaceuticals, Industries Ltd (“Teva”) was determined to be a related party because a member of the Company’s board of directors was the President and CFO of Teva Pharmaceuticals’ North America Commercial through June 2021. In addition, Teva was a non-significant shareholder of the Company during the year. As of December 31, 2020, short-term and long-term deferred revenue from this customer was not material. As of December 31, 2020, there were no amounts due from Teva. Prior to the board member’s departure from the board of directors in June 2021, the Company recognized an immaterial amount of revenue from contracts with this customer. During the years ended, December 31, 2020 and 2019, the Company recognized an immaterial amount of revenue from contracts with this customer. Philips Holding USA, Inc. Philips Holding USA, Inc. (“Philips”) was determined to be a related party because a member of the Company’s board of directors was the Business Leader of Philips Population Health Management through June 2021. In addition, Philips is a non-significant shareholder of the Company. As of September 30, 2021 it was determined Philips was no longer a related party. As of December 31, 2020, the Company held short-term and long-term deferred revenue of $1,458 from contracts with this customer. As of December 31, 2020 amounts due from Philips were $763. Prior to the board member’s departure from Philips in June 2021, the Company recognized revenue of $1,658, from contracts with this customer. During the years ended December 31, 2020 and 2019, the Company recognized revenue of $2,441, $1,021, respectively, from contracts with this customer. Anthem Inc. Anthem Inc. (“Anthem”) was determined to be a related party because a member of the Company’s board of directors served as the Vice President of Anthem through February 2021. In addition, Anthem is a non-significant shareholder of the Company. As of March 31, 2021, it was determined Anthem was no longer a related party. As of December 31, 2020, the Company held short-term and long-term deferred revenue of $11,347 from contracts with this customer. As of December 31, 2020, amounts due from Anthem were $8,391. Prior to the board member’s departure from Anthem in February 2021, the Company recognized revenue of $7,218 from contracts with this customer. During the years ended December 31, 2020 and 2019, the Company recognized revenue of $55,180 and $34,095, respectively, from contracts with this customer. Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of December 31, 2021 and 2020, the Company held short-term and long-term deferred revenue of $456 and $606, respectively from contracts with this customer. As of December 31, 2021 and 2020, amounts due from Cleveland Clinic were $441 and $1,020. During the years ended December 31, 2021, 2020 and 2019, the Company recognized revenue of $1,301, $1,357, and $1,262, respectively, from contracts with this customer. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a less than majority owned interest in. During the year ended December 31, 2020 the Company made an initial investment in CCAW, JV LLC of $2,940 for its less than 50% interest in the joint venture. During the year ended December 31, 2021 the Company made a capital contributed of $2,548, related to a portion of the phase one capital commitment. During the year ended December 31, 2021 and 2020 the Company recognized revenue of $1,841 and $1,825 from contracts with this customer. As of December 31, 2021 and 2020, the Company held short and long term deferred revenue of $1,426 and $1,496 from contracts with this customer. As of December 31, 2021 amounts due from CCAW, JV LLC were $1,613 and as of December 31, 2020, amounts due from CCAW, JV LLC were not material. Loans to Officer During 2020, the Company entered into secured promissory notes with the Chief Financial Officer and other executive officers in the amount of $16,441. These loans were to fund the taxes associated with the restricted stock units and were collateralized by all of the capital stock of the Company that the employee owned or would own in the future and the employees’ personal assets. These loans are recorded within prepaids and other current assets in the Company’s consolidated balance sheet. All outstanding loans with officers were repaid in August 2020 prior to the Company’s IPO.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	19. Employee Benefit Plan The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis, subject to legal limitations. Company contributions to the plan may be made at the discretion of the Company’s board of directors. The Company contributed a total of $2,698, $2,165 and $1,966 to the plan for the years ended December 31, 2021, 2020 and 2019, respectively.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share	20. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Years Ended December 31, 2021 2020 2019 Numerator: Net loss $ (176,782 ) $ (228,626 ) $ (88,366 ) Net loss attributable to non-controlling interest (448 ) (4,194 ) (1,176 ) Net loss attributable to American Well Corporation $ (176,334 ) $ (224,432 ) $ (87,190 ) Denominator: Weighted-average common shares outstanding, basic and diluted 254,068,942 99,044,312 41,138,798 Net loss per share attributable to common stockholders, basic and diluted $ (0.69 ) $ (2.27 ) $ (2.12 ) The Company’s potential dilutive securities, which include stock options, convertible preferred stock and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Years Ended December 31, 2021 2020 2019 Convertible preferred stock (as converted to common stock) — — 123,313,703 Unvested restricted stock units 7,472,787 5,399,622 2,322,408 Options to purchase shares of common stock 15,893,755 23,167,514 24,917,003 23,366,542 28,567,136 150,553,114

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”) (see Note 4) and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 5). Intercompany accounts and transactions have been eliminated in consolidation. For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net income (loss) attributable to noncontrolling interests is recorded in the consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions.
Foreign Currency	Foreign Currency The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2021, the Company’s gains (losses) from foreign currency remeasurement and settlement were $445. During the years ended December 31, 2020 and 2019, the Company’s gains or losses from foreign currency remeasurement and settlements were insignificant.
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of December 31, 2021 and 2020, one customer accounted for 19% and 19% of outstanding accounts receivable, respectively. For the years ended December 31, 2021, 2020 and 2019, sales to one related party customer represented 25%, 22% and 23% of the Company’s total revenue, respectively.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less at the date of purchase to be cash equivalents.
Restricted Cash	Restricted Cash As of December 31, 2021 and 2020, the Company maintained letters of credit totaling $795 and $1,095, respectively, for the benefit of the landlord of its leased property and performance surety bonds. The Company has classified $0 and $1,095 as current as of December 31, 2021 and 2020, respectively, and $795 and $0 as non-current on its consolidated balance sheet as of December 31, 2021 and 2020, respectively.
Investments	Investments The Company’s investments are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in total stockholders’ equity (deficit). The Company has classified its available-for-sale investments as current assets on the consolidated balance sheet as these investments generally consist of highly marketable securities that are identified to be available to meet near-term cash requirements. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of interest income and other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company periodically evaluates its investments for other-than-temporary impairment. When assessing investments for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be “other than temporary,” the Company reduces the investment through a charge to the consolidated statement of operations and other comprehensive income (loss). No such adjustments were necessary during the periods presented. As of December 31, 2021 and 2020, there were no investments that had been in a continuous loss position for more than 12 months.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Inventories	Inventories The Company values all of its inventories, which consist primarily of raw material hardware components, at the lower of cost or net realizable value on a first-in, first-out basis (“FIFO”). Write-offs of potentially slow moving or damaged inventory are recorded through specific identification of obsolete or damaged material.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method over the useful life of the assets. Computer equipment is depreciated over three to four years. Computer software, furniture and fixtures and office equipment are depreciated over three years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Repairs and maintenance costs are expensed as incurred. When assets are sold or retired, the cost and related accumulated depreciation or amortization are removed from the accounts, with any resulting gain or loss recorded in the consolidated statements of operations and comprehensive loss.
Business Combinations	Business Combinations The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. Transaction costs related to business combinations are expensed as incurred in general and administrative expense in the consolidated statement of operations and comprehensive loss. Determining the fair value of assets acquired and liabilities assumed, and the allocation of the purchase price requires management to use judgment and estimates with regards to the selection of valuation methodologies, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, significant assumptions related to estimates of future revenue and cash flows, expected long-term market growth, expected revenue growth rates, future expected operating expenses, earnings before interest, taxes, depreciation and amortization margin, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, which could last up to one year after the transaction date, all adjustments are recorded in the consolidated statements of operations and comprehensive loss.
Goodwill	Goodwill The Company recognizes the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. The Company’s goodwill impairment tests are performed at the enterprise level given the Company’s single reporting unit. The fair value of the reporting unit is estimated using quoted market prices in active markets of the Company’s stock. Declines in market capitalization are assessed to determine whether they would indicate a triggering event. As part of the Step 1 analysis the Company considers assumptions such as control premium, market data and expected future cash flows, as needed. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied the fair value. The Company’s annual goodwill impairment test resulted in no impairment charges in any of the periods in the consolidated financial statements.
Intangible Assets	Intangible Assets Intangible assets acquired in a business combination are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired and reported net of accumulated amortization, separately from goodwill. Finite-lived intangible assets, which primarily consist of customer relationships, contractor relationships, technology and trade name, are stated at historical cost and amortized over the assets’ estimated useful lives.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets, among others. When testing for asset impairment, the Company groups assets and liabilities at the lowest level for which cash flows are separately identifiable. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than the asset’s carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value. To date, the Company has not recorded any impairment losses on long-lived assets. No events or changes in circumstances existed to require an impairment assessment during the years ended December 31, 2021 and 2020.
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. During the year ended December 31, 2020, the Company contributed $2,940 as its initial investment for a 49% interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $11,800 in two phases, which is yet to be defined. In February 2021 the Company made a capital contribution of $2,548 related to a portion of the phase one capital commitment. For the year ended December 31, 2021 and 2020, the Company recognized a loss of $3,132 and $2,188 as its proportionate share of the joint ventures results of operations, respectively. Accordingly, the carrying value of the equity method investment as of December 31, 2021 and 2020 was $168 and $752, respectively.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense in the consolidated statement of operations and comprehensive loss. For the years ended December 31, 2021, 2020 and 2019, the Company’s advertising expenses were $5,604, $3,860 and $6,107, respectively.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses include payroll, employee benefits and other expenses associated with product development.
Internal-Use Software	Internal-Use Software The Company evaluates development costs incurred in connection with its internal-use software for capitalization. Qualifying costs incurred to develop internal-use software are capitalized when (i) the preliminary project stage is completed, (ii) management has authorized further funding for the completion of the project and (iii) it is probable that the project will be completed and performed as intended. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Capitalized internal-use software development costs are amortized using the straight-line method over an estimated useful life of three years. Such amortization expense for internal-use software is classified as cost of revenues in the consolidated statements of operations and comprehensive loss. Capitalized internal-use software costs were not material to the Company’s consolidated financial statements during the years ended December 31, 2021 and 2020.
Stock-Based Compensation	Stock-Based Compensation The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. Generally, the Company issues stock options and restricted stock units (“RSU’s”) to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. Stock option awards and restricted stock units issued to the co-CEOs prior to the IPO or as a result of the IPO (“IPO RSUs”) were expensed when granted as the requisite future service of the awards is not substantive for accounting purposes. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award’s recipient’s payroll costs are classified. The Company recognizes compensation expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate, the Company has considered its historical experience to estimate pre-vesting forfeitures for service-based awards. The impact of a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual forfeiture rate is materially different from the Company’s estimate, the Company may be required to record adjustments to stock-based compensation expense in future periods. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The restricted stock units issued to the co-CEOs as a result of the IPO had the fair value estimated using a binomial lattice approach. The Company historically had been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
Deferred Contract Acquisition Costs	Deferred Contract Acquisition Costs The Company capitalizes sales commissions and certain parts of the Company bonus that are incremental to the acquisition of customer contracts. These costs are recorded as deferred contract acquisition costs on the consolidated balance sheets. The Company determines whether costs should be deferred based on its sales compensation plans if the commissions are in fact incremental and would not have occurred absent the customer contract. Sales commissions are paid upon the initial acquisition of a contract and are amortized over an estimated period of benefit of five years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The Company determined the period of benefit for commissions paid for the acquisition of initial contracts by taking into consideration the commitment term of the customer contract, the nature of the Company’s technology development life cycle, and an estimated customer relationship period. Amortization of deferred contract acquisition costs is included in sales and marketing expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company reviews these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit of these deferred contract acquisition costs. There were no impairment losses recorded during the periods presented.
Deferred Contract Fulfillment Costs	Deferred Contract Fulfillment Costs The Company capitalizes costs to fulfill contracts with customers in “Prepaid expenses and other current assets” and “Other assets” on its consolidated balance sheet. The Company amortizes these costs to cost of revenue in the consolidated statement of operations and comprehensive loss consistent with the revenue recognition of the performance obligations in the associated contracts. The Company assesses these costs for impairment at the end of each reporting period. There were no impairment losses recorded during the periods presented.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income, and to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by considering taxable income in carryback years, existing taxable temporary differences, prudent and feasible tax planning strategies and estimating the future taxable profits. The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net Loss per Share	Net Loss per Share The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income or losses for the period had been distributed. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net losses attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. The Company’s convertible preferred stock contractually entitles the holders of such shares to participate in dividends, but contractually does not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued, as their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2021, 2020 and 2019.
Revenue Recognition	Revenue Recognition Platform subscription The Company generates revenue primarily from contracts with customers who purchase subscriptions to access the Company’s hosted telehealth platform which includes access to the Company’s affiliated medical group. The Company’s customers do not have the right to take possession of the Company’s software operating its telehealth platform at any time. Instead, customers are granted access to the Company’s platform over the contractual period. Access to the platform, including the stand ready obligation to provide access to the affiliated medical group, represents a series of distinct services as the Company continually provides access to and fulfills its obligation to the customer over the contract term. The typical contract term is three years. Most of the Company’s contracts are non-cancelable over the contractual term. Customers typically have the right to terminate their contracts for cause if the Company fails to perform in accordance with the contractual terms. For customers who purchase access to the enterprise telehealth platform (the “Amwell Platform”), the Company hosts a dedicated instance of the Amwell Platform, white-labeled under the customer’s own name, branding, and with customized workflows and operating choices. The implementation services for the Amwell Platform are not distinct within the context of the contract because the Company’s promise to perform the implementation services are not separately identifiable from the access to the Amwell Platform. The implementation services, which customize the customer’s Amwell Platform, are integral to the customer’s ability to derive its intended benefit from the Amwell Platform. The development and implementation services generally span several months and cannot be performed by another entity. Therefore, access to the Amwell Platform and the implementation services are bundled together and represent a single performance obligation. The fixed consideration related to the single performance obligation is generally recognized on a straight-line basis over the contract term beginning on the date access to the Amwell Platform is provided. The Company uses a time-elapsed method to measure progress because the Company transfers control evenly over the contractual period. Customers can also purchase access to the Company’s co-branded telehealth practice hosted on the Company’s shared services platform (the “Amwell Practice”). The implementation services for the Amwell Practice do not significantly modify or customize the Amwell Practice, typically occur over a few days, and can be performed by other entities. Therefore, access to the Amwell Practice and the implementation services are separate outputs promised by the Company and represent two distinct performance obligations. Customers may be billed prior to the related goods or services being transferred to the customer. In determining the transaction price, the Company adjusts the promised amount of consideration for a significant financing component if the timing of payments agreed to by the parties in the contract provide the customer a significant benefit of financing. The Company has applied the practical expedient and recognizes the promised amount of consideration without adjusting for the effects of a significant financing component if the Company expects, at contract inception, that the period between the transfer of goods or services to the customer when the customer pays for that good or service will be one year or less. As of December 31, 2021, the effect of the financing component is not significant and does not materially change the amount of revenue that would be recognized under a contract. The total fixed consideration is allocated to each distinct performance obligation based on standalone selling price (“SSP”) which reflects the amount that the Company charges for each performance obligation if it was sold separately in a standalone sale. The fixed consideration to access the Amwell Practice is recognized on a straight-line basis over the contract term beginning on the date access to the Amwell Practice is provided. A time-elapsed method is used to measure progress because the Company transfers control evenly over the contractual period. The fixed consideration related to the implementation services is recognized as the services are performed. In addition to the fixed consideration received from the Amwell Platform and Amwell Practice, the Company can also receive variable consideration based on the number of members serviced (that is, a stated fee per member per month). The Company allocates the per member per month variable consideration to the month that the fee is earned, correlating with the amount of services it is providing, which is consistent with the allocation objective of the series guidance. Revenue recognized from the per member per month variable consideration does not represent a significant portion of total revenue for the years ended December 31, 2021 , 2020 and 2019 . Some contracts with customers contain a renewal option which allows the customer to continue access to the Amwell Platform for a stated price after the initial contractual term has ended. These renewal options are evaluated on a case-by-case basis but generally do not provide a material right as they are priced at or above the price for the same service that the Company offers to similar customers and, as such, would not result in a separate performance obligation. Visits The Company also generates revenue when either the Amwell Platform or the Amwell Practice is utilized to conduct a medical visit. In the event of a visit, the fee that is earned upon completion of the visit is allocated to the specific day of performance, as the visit fee meets the criteria to allocate variable consideration to a distinct service within a series of distinct services that comprise the single performance obligation. Therefore, visit fees are recognized when the visits are completed, and the Company has delivered on its stand-ready obligation to provide access to the medical professional. In addition, customers can visit with the Company’s affiliated medical group without purchasing access to an Amwell Platform or Amwell Practice. These direct-to-consumer telehealth visits are available through the Company’s website where customers can conduct a visit with the Company’s affiliated medical group for a fixed fee. The Company’s affiliated medical group is responsible for fulfilling the promise to the customer to perform the medical visit. The Company has discretion in establishing the price for the visit, is responsible for the resolution of any customer issues, and is exposed to credit risk for the receivable due from the customer. Therefore, the Company recognizes the visit fee on a gross basis upon completion of the visit. Other Other revenue primarily represents professional services associated with the Amwell Platform. After implementation of Amwell Platform has been completed, some customers purchase other professional services, which are designed to help customers enhance their ability to use Amwell Platform. For the majority of arrangements, the Company prices these professional services on a time and material basis, has standalone selling price for these services, and recognizes revenue as services are performed. Other revenue also includes sale of hardware products, such as the Company’s telehealth carts and kiosks. Revenue from the sale of hardware products to customers is recognized upon the transfer of control, which occurs upon shipment of the product.
Deferred Revenue	Deferred Revenue Deferred revenue includes amounts collected or billed in excess of revenue recognized. Deferred revenue is recognized as revenue as the related performance obligations are satisfied. Deferred revenue that will be recognized during the succeeding twelve-month period is recorded as a current liability and the remaining portion is recorded as a noncurrent liability on the consolidated balance sheet.
Leases	Leases The Company determines at the inception of a contract if such arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded on the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company’s contracts may contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company determines the present value of future lease payments by using its estimated secured incremental borrowing rate for that lease term as the interest rate implicit in the lease is not readily determinable. The Company estimates its secured incremental borrowing rate for each lease based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term. Certain of the Company’s leases include options to extend or terminate the lease. The amounts determined for the Company’s right-of-use assets and lease liabilities generally do not assume that renewal options or early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In January 2017, the FASB issued ASU No. 2017-04, Goodwill Simplifications (Topic 350) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments—Credit Losses Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief

Revenue and Deferred Revenue (T

Revenue and Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Years Ended December 31, 2021 2020 2019 Platform subscription $ 108,254 $ 98,361 $ 83,705 Visits 116,617 117,181 40,701 Other 27,918 29,723 24,451 Total Revenue $ 252,789 $ 245,265 $ 148,857
Summary of Significant Changes in the Company's Deferred Revenue	Significant changes in the Company’s deferred revenue balance for the years ended December 31, 2021, 2020 and 2019: Years Ended December 31, 2021 2020 2019 Total deferred revenue, beginning of the period $ 74,800 $ 77,386 $ 93,299 Additions 123,717 109,542 85,167 Recognized (122,621 ) (112,128 ) (101,080 ) Total deferred revenue, end of the period $ 75,896 $ 74,800 $ 77,386 Current deferred revenue 68,841 66,693 66,490 Non-current deferred revenue 7,055 8,107 10,896 Total $ 75,896 $ 74,800 $ 77,386

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: December 31, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 671,107 $ — $ — $ 671,107 Investments — — — — Total financial assets: Contingent consideration — — 16,450 16,450 Total financial liabilities: $ 671,107 $ — $ 16,450 $ 687,557 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 892,934 $ — $ — $ 892,934 Investments — 99,963 — 99,963 $ 892,934 $ 99,963 $ — $ 992,897
Summary of Contingent Earnout Payments for Each Acquisition	Year Ended December 31, 2021 Beginning Balance as of January 1 $ — Initial estimate of fair value related to SilverCloud contingent consideration 29,360 Initial estimate of fair value related to Conversa contingent consideration 15,230 Accretion of contingent consideration 600 Fair value adjustment (13,740 ) Earned amount due to shareholders (15,000 ) Ending Balance $ 16,450

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Debt securities, available-for-sale	As of December 31, 2021 and 2020, the fair value of the Company’s investments by type of security was as follows: December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ — December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ 99,854 $ 109 $ — $ 99,963 99,854 109 — 99,963

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Summary of Changes in the Allowance for Credit Losses	Changes in the allowance for credit losses were as follows: Years Ended December 31, 2021 2020 2019 Allowance for credit losses, beginning of the period $ 1,556 $ 686 $ 396 Provisions 714 1,646 717 Write-offs (461 ) (776 ) (427 ) Allowance for credit losses, end of the period $ 1,809 $ 1,556 $ 686

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2021
Business Acquisition [Line Items]
Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives	The following are the identifiable intangible assets acquired in the August 2021 SilverCloud Weighted Average Life (Years) Conversa Health Weighted Average Life (Years) Technology $ 34,996 5.0 $ 20,400 5.0 Tradename 10,800 7.0 4,200 5.0 Customer relationships 32,350 10.0 10,100 10.0 Total $ 78,146 $ 34,700
Schedule of Identifiable Assets Acquired and Liabilities Assumed	Identifiable assets acquired and liabilities assumed (in thousands): SilverCloud Conversa Health Purchase consideration: Cash consideration, net of cash acquired $ 105,195 $ 51,331 Stock consideration 85,571 52,160 Contingent consideration 29,360 15,230 Escrow share consideration 6,376 Working capital adjustment (300 ) (127 ) Total consideration transferred $ 226,202 $ 118,594 Allocation of Consideration transferred: Accounts receivable $ 2,630 $ 3,651 Identifiable intangible assets 78,146 34,700 Other assets 491 4,604 Total assets acquired 81,267 42,955 Current liabilities 2,155 8,463 Deferred revenue 5,813 4,655 Other long-term liabilities 11,557 115 Total liabilities assumed 19,525 13,233 Goodwill $ 164,460 $ 88,872 $ 226,202 $ 118,594
Aligned Tele-health Inc. [Member]
Business Acquisition [Line Items]
Summary of Final Allocation of Assets Acquired and Liabilities Assumed	The final allocation of the purchase consideration of $82,948 is as follows: Aligned Cash $ 2,938 Accounts receivable 3,612 Identifiable intangible assets 14,100 Other assets 179 Total assets acquired 20,829 Current liabilities (3,102 ) Deferred tax liability (1,388 ) Total liabilities assumed (4,490 ) Goodwill 66,609 Total purchase consideration $ 82,948
Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives	The following are the identifiable intangible assets acquired and their respective weighted average useful lives, as determined based on final valuations: Aligned Weighted Average Life (Years) Customer relationships $ 13,800 7.0 Trade name 300 7.0 Total $ 14,100

Deferred Contract Acquisition_2

Deferred Contract Acquisition and Contract Fulfillment Costs (Tables)	12 Months Ended
	Dec. 31, 2021
Contract Acquisition Cost [Member]
Capitalized Contract Cost [Line Items]
Capitalized Contract Cost	The following table represents a rollforward of the Company’s deferred contract acquisition costs: December 31, 2021 2020 Beginning balance as of January 1 $ 3,461 $ 2,769 Additions to deferred contract acquisition costs 2,235 2,102 Amortization of deferred contract acquisition costs (1,971 ) (1,410 ) Ending balance $ 3,725 $ 3,461 Deferred contract acquisition costs, current $ 1,697 $ 2,134 Deferred contract acquisition costs, noncurrent 2,028 1,327 Total $ 3,725 $ 3,461
Contract Fulfillment Cost [Member]
Capitalized Contract Cost [Line Items]
Capitalized Contract Cost	The following table represents a rollforward of the Company’s deferred contract fulfillment costs: December 31, 2021 2020 Beginning balance as of January 1 $ 1,861 $ 2,086 Additions to deferred contract fulfillment costs 266 627 Amortization of deferred contract fulfillment costs (737 ) (852 ) Ending balance $ 1,390 $ 1,861 Deferred contract fulfillment costs, current $ 736 $ 624 Deferred contract fulfillment costs, noncurrent 654 1,237 Total $ 1,390 $ 1,861

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Property and equipment, net consisted of the following: As of December 31, 2021 2020 Furniture and fixtures $ 231 $ 930 Computer and office equipment 7,965 7,638 Computer software 5,086 4,847 Leasehold improvements 692 2,162 13,974 15,577 Less: Accumulated depreciation and amortization (11,739 ) (11,741 ) Property and equipment, net $ 2,235 $ 3,836

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following as of: December 31, 2021 2020 Beginning Balance as of January 1 $ 193,877 $ 193,877 Goodwill acquired 253,332 Currency translation adjustments (4,448 ) — Ending Balance $ 442,761 $ 193,877
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following as of: Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2021 Customer relationships $ 81,053 $ (16,842 ) $ 64,211 8.2 Contractor relationships 535 (247 ) 288 7.0 Trade name 14,435 (706 ) 13,729 5.8 Technology 90,464 (16,283 ) 74,181 5.0 $ 186,487 $ (34,078 ) $ 152,409 Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2020 Customer relationships $ 38,782 $ (11,380 ) $ 27,402 7.0 Contractor relationships 535 (206 ) 329 8.0 Trade name 300 (300 ) — — Technology 37,063 (9,266 ) 27,797 7.5 $ 76,680 $ (21,152 ) $ 55,528
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of December 31, 2021, is as follows: 2022 $ 25,039 2023 25,039 2024 25,055 2025 25,039 2026 20,617 Thereafter 31,620 152,409

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following: As of December 31, 2021 2020 Employee compensation and benefits $ 21,572 $ 20,521 Professional services 8,766 6,832 Earned contingent consideration 15,000 — Provider services 5,473 4,632 Other 7,900 10,150 Total $ 58,711 $ 42,135

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders Equity Note [Abstract]
Convertible Preferred Stock	The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Authorized Shares Issued Shares Outstanding Liquidation Preference Carrying Value Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799
Schedule of Common Stock	In the year ended December 31, 2021 4,079,035 shares of Class B common stock were converted to Class A common stock. As of December 31, 2021 the par value of the Class A, Class B and Class C shares was $2,294, $270 and $56, respectively. Shares Authorized Shares Issued Shares Outstanding Class A 1,000,000,000 229,402,453 229,402,453 Class B 100,000,000 26,913,579 26,913,579 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 261,871,587 261,871,587
Activity under Plans	Activity under the Plans is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2021 23,167,514 $ 4.37 6.2 $ 487,758 Granted — $ — Forfeited (578,503 ) $ 5.82 Expired — $ — Exercised (6,695,256 ) $ 3.21 Outstanding as of December 31, 2021 15,893,755 $ 4.81 5.9 $ 23,876 Vested and expected to vest as of December 31, 2021 15,395,398 $ 4.61 5.8 $ 23,752 Options exercisable as of December 31, 2021 13,407,882 $ 4.38 5.5 $ 23,120
Weighted Average of Assumptions used to Determine Fair Value of Common Stock Options Granted	The weighted average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Years Ended December 31, 2021 2020 2019 Risk-free interest rate N/A 1.09 % 2.17 % Expected term (in years) N/A 6.1 6.0 Expected volatility N/A 52 % 50 % Expected dividend yield N/A 0 % 0 %
Summary of Unvested Restricted Stock Unit Activity	The following table summarizes the unvested restricted stock unit activity for the year ended December 31, 2021: Shares Weighted Average Grant Date Fair Value Unvested as of January 1, 2021 11,014,450 $ 14.43 Granted 9,011,024 16.93 Vested (7,394,144 ) 9.34 Forfeited (912,517 ) 13.62 Unvested as of December 31, 2021 11,718,813 $ 19.63
Stock-Based Compensation Expense	Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows: Years Ended December 31, 2021 2020 2019 Cost of revenues $ 1,655 $ 1,087 $ 536 Research and development 7,613 4,793 1,477 Selling and marketing 7,666 4,147 2,418 General and administrative 26,875 108,331 7,704 Total $ 43,809 $ 118,358 $ 12,135

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Summary of Lease Cost	Years Ended December 31, 2021 2020 2019 The components of lease cost under ASC 842 were as follows: Operating lease cost $ 5,617 $ 6,632 $ 6,649 Short-term lease cost — — — Variable lease cost — — — Total lease cost $ 5,617 $ 6,632 $ 6,649 Years Ended December 31, 2021 2020 2019 Supplemental cash flow information: Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 6,352 $ 7,006 $ 6,480 Non-cash lease activity: Right-of-use lease assets obtained in exchange for new operating lease liability: Operating leases $ 15,506 $ 417 $ 355 As of December 31, 2021 2020 Supplemental balance sheet information related to leases is as follows: Operating leases Operating lease right-of-use assets $ 16,422 $ 6,609 Total operating right-of-use lease assets $ 16,422 $ 6,609 Operating lease liabilities, current 1,918 6,357 Operating lease liabilities, net of current portion 14,694 1,296 Total operating lease liabilities $ 16,612 $ 7,653 Weighted-average remaining lease term (in years) 5.0 years 1.3 years Weighted-average discount rate 1.1 % 2.9 %
Summary of Minimum Future Lease Payments for These Operating Leases	As of December 31, 2021, minimum future lease payments for these operating leases were as follows: Years ending December 31, 2022 $ 2,100 2023 3,683 2024 3,416 2025 3,484 2026 3,554 Thereafter 893 Total lease payments $ 17,130 Less imputed interest (518 ) Total present value of lease liabilities $ 16,612

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Components of Current and Deferred Portions of Provision for Income Taxes	The components of our current and deferred portions of the provision for income taxes are presented in the table below: Years Ended December 31, 2021 2020 2019 Current income tax provision (benefit): Federal $ — $ — $ — State 41 97 34 Foreign 828 448 285 Total Current $ 869 $ 545 $ 319 Deferred income tax provision (benefit): Federal $ (5,730 ) $ 103 $ (821 ) State 1 21 (252 ) Foreign (516 ) (30 ) (49 ) Total Deferred $ (6,245 ) $ 94 $ (1,122 ) Total provision (benefit) for income taxes $ (5,376 ) $ 639 $ (803 )
Summary of Reconciliation of Federal Statutory Rate and Provision for Income Taxes	The following reconciles the differences between income taxes computed at the federal statutory rate and the provision for income taxes: Years Ended December 31, 2021 2020 2019 Federal statutory income tax rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 4.5 2.0 3.0 Valuation allowance (24.5 ) (13.3 ) (21.3 ) Stock-based compensation 1.9 (9.5 ) (1.1 ) Other 0.1 (0.5 ) (0.7 ) Effective income tax rate 3.0 % (0.3 %) 0.9 %
Summary of Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred tax assets and liabilities were as follows: As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 179,555 $ 116,965 Research and development credit carryforwards 1,676 2,081 Deferred revenue 2,863 4,848 Deferred compensation 7,176 7,142 Startup costs 84 171 Leasing obligation 4,115 1,937 Other 904 1,030 Total deferred tax assets 196,373 134,174 Total valuation allowance (164,391 ) (118,795 ) Total net deferred tax assets 31,982 15,379 Joint venture investment basis difference (1,453 ) (1,706 ) Intangibles (30,265 ) (10,563 ) Right-of-use assets (4,068 ) (1,669 ) Other (1,131 ) (1,374 ) Total deferred tax assets (liabilities) (36,917 ) (15,312 ) Net deferred tax liabilities $ (4,935 ) $ 67
Summary of Changes in Valuation Allowance for Deferred Tax Assets	Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021, 2020 and 2019 related primarily to the increase in net operating loss carryforwards in 2021, 2020 and 2019 and were as follows: Years Ended December 31, 2021 2020 2019 Valuation allowance as of beginning of the year $ 118,795 $ 88,499 $ 69,433 Increases recorded to income tax provision 51,348 30,296 20,454 Decreases recorded as a benefit to income tax provision (5,752 ) — (1,388 ) Valuation allowance as of end of year $ 164,391 $ 118,795 $ 88,499

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Years Ended December 31, 2021 2020 2019 Numerator: Net loss $ (176,782 ) $ (228,626 ) $ (88,366 ) Net loss attributable to non-controlling interest (448 ) (4,194 ) (1,176 ) Net loss attributable to American Well Corporation $ (176,334 ) $ (224,432 ) $ (87,190 ) Denominator: Weighted-average common shares outstanding, basic and diluted 254,068,942 99,044,312 41,138,798 Net loss per share attributable to common stockholders, basic and diluted $ (0.69 ) $ (2.27 ) $ (2.12 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Years Ended December 31, 2021 2020 2019 Convertible preferred stock (as converted to common stock) — — 123,313,703 Unvested restricted stock units 7,472,787 5,399,622 2,322,408 Options to purchase shares of common stock 15,893,755 23,167,514 24,917,003 23,366,542 28,567,136 150,553,114

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Aug. 27, 2021	Aug. 09, 2021	Sep. 21, 2020	Aug. 22, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of Class C shares in connection with Google Private Placement							$ 99,100
Description of the stock split arrangement						8.8-for-1.0
Proceeds from issuance of common stock							99,100
Proceeds from private placement			$ 100,000
Accumulated deficit						$ 811,284	$ 582,359
Common Class A [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, initial public offering					45,681,499
Net proceeds from IPO					$ 767,568
Underwriting discounts and commissions					$ 49,336
Common Class C [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, initial public offering					5,555,555
Issuance of Class C shares in connection with Google Private Placement				$ 100,000	$ 99,100	$ 99,100
Issuance of Class C shares in connection with Google Private Placement, Shares				5,555,555
Payments of stock issuance costs				$ 900	$ 900
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock			$ 822,267
IPO [Member] | Common Class A [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, initial public offering			45,681,499
Shares issued, price per share			$ 18
Net proceeds from IPO			$ 767,568
Underwriting discounts and commissions			49,336
Other offering costs			$ 4,906
Convertible preferred stock, shares issued upon conversion			136,625,900
Conversa Health Inc. [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Effective date of acquisition		Aug. 9, 2021
Silver Cloud Health Holdings, Inc. [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Effective date of acquisition	Aug. 27, 2021

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Feb. 28, 2021USD ($)	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Gain (losses) from foreign currency remeasurement and settlement		$ 445,000
Number of reportable segment | Segment		1
Number of operating segment | Segment		1
Letter of credit, Total		$ 795,000	$ 1,095,000
Restricted cash, current		0	1,095,000
Restricted cash, noncurrent		795,000	0
Investments in a continuous unrealized loss position for more than twelve months		0	0
Impairment loss on goodwill		0
Impairment of long-lived assets		0
Payment to acquire interest in joint venture		2,548,000	2,940,000
Share of the net profit loss in the operations of joint venture		(3,132,000)	(2,188,000)
Advertising expenses		5,604,000	3,860,000	$ 6,107,000
Impairment losses		$ 0
Percentage of uncertain income taxes to be realized for recognizing in the income statement		50.00%
Accounting Standards Update 2018-13 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Accounting Standards Update 2018-15 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Accounting Standards Update 2019-12 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Accounting Standards Update 2021-08 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Jul. 1, 2021
Accounting Standards Update 2017-04 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Accounting Standards Update 2016-13 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]		true
Change in accounting principle, accounting standards update, adoption date		Dec. 31, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture			$ 2,940,000
Percentage of ownership interest in joint venture			49.00%
Estimated additional total capital contributions necessary		$ 11,800,000
Additional capital contribution related to portion of phase one capital commitment	$ 2,548,000
Share of the net profit loss in the operations of joint venture		(3,132,000)	$ (2,188,000)
Equity method investment carrying value		$ 168,000	$ 752,000
Computer Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Furniture and Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Office Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Software Development Costs [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life		3 years
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		19.00%	19.00%
Customer Concentration Risk | Revenue Benchmark [Member] | Related Party Customer One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		25.00%	22.00%	23.00%
Minimum [Member] | Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities		100.00%
Maximum [Member] | Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life		4 years

Revenue and Deferred Revenue -

Revenue and Deferred Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total Revenue	$ 252,789	$ 245,265	$ 148,857
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	108,254	98,361	83,705
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	116,617	117,181	40,701
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 27,918	$ 29,723	$ 24,451

Revenue and Deferred Revenue _2

Revenue and Deferred Revenue - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognized	$ 56,473	$ 53,601	$ 59,006
Transaction price allocated to remaining performance obligations	$ 219,893	$ 192,238
Performance obligation percentage of transaction price to recognized in the next twelve months	46.00%	46.00%
Other Assets [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled accounts receivable	$ 781
Unbilled Revenues [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled accounts receivable	$ 5,697	$ 3,376

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Total deferred revenue, beginning of the period	$ 74,800	$ 77,386	$ 93,299
Additions	123,717	109,542	85,167
Recognized	(122,621)	(112,128)	(101,080)
Total deferred revenue, end of the period	$ 75,896	$ 74,800	$ 77,386

Revenue - Summary of Contract_2

Revenue - Summary of Contract with Customer Liability Current and Non Current (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Current deferred revenue	$ 68,841	$ 66,693	$ 66,490
Non-current deferred revenue	7,055	8,107	10,896
Total	$ 75,896	$ 74,800	$ 77,386	$ 93,299

Revenue and Deferred Revenue _3

Revenue and Deferred Revenue - Additional Information (Detail1)	Dec. 31, 2021	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-12-31
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years	3 years

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Total assets	$ 1,445,836	$ 1,376,646
Total liabilities	184,961	130,449
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Total assets	29,770	22,682
Total liabilities	1,485	1,998
Total revenue	$ 72,125	$ 78,396	$ 23,450

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Loss attributed to non-controlling interest	$ 448	$ 4,194	$ 1,176
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 21,617	$ 22,065	$ 26,259
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				50.00%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				100.00%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets		$ 992,897
Total financial liabilities	$ 687,557
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	16,450
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	671,107	892,934
Investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets		99,963
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets		892,934
Total financial liabilities	671,107
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	671,107	892,934
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets		99,963
Fair Value, Inputs, Level 2 [Member] | Investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets		$ 99,963
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	16,450
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial liabilities	$ 16,450

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer from level one to level two fair value assets	$ 0	$ 0
Transfer from level one to level three fair value assets	0	0
Transfer from level two to level one fair value assets	0	0
Transfer from level three to level one fair value assets	0	$ 0
Decrease in fair value of the contingent earnout consideration	$ 13,740
Silver Cloud Health Holdings, Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Revenue discount rate of earnout payment	3.10%
Conversa Health Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Revenue discount rate of earnout payment	1.30%
Contingent earnout consideration payable to shareholders	$ 15,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Contingent Earnout Payments for Each Acquisition (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Business Acquisition Contingent Consideration [Line Items]
Accretion of contingent consideration	$ 600
Fair value adjustment	(13,740)
Earned amount due to shareholders	(15,000)
Ending Balance	16,450
Silver Cloud Health Holdings, Inc. [Member]
Business Acquisition Contingent Consideration [Line Items]
Initial estimate of fair value related to contingent consideration	29,360
Conversa Health Inc. [Member]
Business Acquisition Contingent Consideration [Line Items]
Initial estimate of fair value related to contingent consideration	$ 15,230

Investments - Debt Securities,

Investments - Debt Securities, Available-For-Sale (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 99,854
Gross Unrealized Gains	109
Fair Value	99,963
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	99,854
Gross Unrealized Gains	109
Fair Value	$ 99,963

Allowance for Credit Losses - S

Allowance for Credit Losses - Summary of Changes in the Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Allowance for credit losses, beginning of the period	$ 1,556	$ 686	$ 396
Provisions	714	1,646	717
Write-offs	(461)	(776)	(427)
Allowance for credit losses, end of the period	$ 1,809	$ 1,556	$ 686

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($)	Aug. 27, 2021	Aug. 09, 2021	Nov. 30, 2019	Aug. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Business combination contingent consideration payable					$ 16,450,000
Aggregate merger consideration, stock value					144,107,000
Aligned Tele-health Inc. [Member]
Business Acquisition [Line Items]
Business combination, consideration transferred			$ 82,948,000
Payment to acquire business			48,688,000
Business combination contingent consideration transferred			10,000
Business combination contingent consideration payable						$ 70,000,000
Business combination remeasurement adjustment						10,000
Business combination earn-out						0
Acquisition related costs							$ 1,494,000
Contingent earnout consideration payable to shareholders						$ 0
Business combination, purchase consideration			$ 82,948,000
Aligned Tele-health Inc. [Member] | Series C Redeemable Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Business combination consideration in shares issued or issuable			456,667
Business combination equity interests issued or issuable			$ 34,250,000
Silver Cloud Health Holdings, Inc. [Member]
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 226,202,000
Business combination consideration in shares issued or issuable				8,100,000
Payment to acquire business	105,195,000
Business combination contingent consideration payable	40,000,000
Acquisition related costs	4,854,000
Business combination, purchase consideration	$ 226,202,000
Effective date of acquisition	Aug. 27, 2021
Cash acquired from acquisition	$ 12,239,000
Aggregate merger consideration, escrow share consideration	6,376,000
Fair value of contingent consideration of acquisition date	29,360,000
Noncash compensation costs	$ 717,000
Earn-out payout year	2023
Increase or decrease in goodwill of tax attributes of the business combinations		$ 2,825,000
Decrease in goodwill on finalization of net working capital adjustment		9,000
Silver Cloud Health Holdings, Inc. [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Business combination consideration in shares issued or issuable	8,100,000
Aggregate merger consideration, stock value	$ 85,571,000
Conversa Health Inc. [Member]
Business Acquisition [Line Items]
Business combination, consideration transferred		118,594,000
Business combination consideration in shares issued or issuable				4,700,000
Payment to acquire business		51,331,000
Business combination contingent consideration payable		30,000,000
Acquisition related costs		2,435,000
Contingent earnout consideration payable to shareholders					$ 15,000,000
Business combination, purchase consideration		$ 118,594,000
Effective date of acquisition		Aug. 9, 2021
Cash acquired from acquisition		$ 9,735,000
Fair value of contingent consideration of acquisition date		15,230,000
Increase or decrease in goodwill of tax attributes of the business combinations		(1,268,000)
Decrease in goodwill on finalization of net working capital adjustment		$ 66,000
Conversa Health Inc. [Member] | Common Class A [Member]
Business Acquisition [Line Items]
Business combination consideration in shares issued or issuable		4,700,000
Aggregate merger consideration, stock value		$ 52,160,000

Business Combinations - Summary

Business Combinations - Summary of Final Allocation of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2019
Business Acquisition [Line Items]
Goodwill	$ 442,761	$ 193,877	$ 193,877
Aligned Tele-health Inc. [Member]
Business Acquisition [Line Items]
Cash				$ 2,938
Accounts receivable				3,612
Identifiable intangible assets				14,100
Other assets				179
Total assets acquired				20,829
Current liabilities				(3,102)
Deferred tax liability				(1,388)
Total liabilities assumed				(4,490)
Goodwill				66,609
Total purchase consideration				$ 82,948

Business Combinations - Summa_2

Business Combinations - Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives (Detail) - USD ($) $ in Thousands	Aug. 27, 2021	Aug. 09, 2021	Nov. 30, 2019
Aligned Tele-health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired			$ 14,100
Aligned Tele-health Inc. [Member] | Customer relationships [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired			$ 13,800
Weighted Average Life (Years)			7 years
Aligned Tele-health Inc. [Member] | Trade name [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired			$ 300
Weighted Average Life (Years)			7 years
Silver Cloud Health Holdings, Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 78,146
Silver Cloud Health Holdings, Inc. [Member] | Customer relationships [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 32,350
Weighted Average Life (Years)	10 years
Silver Cloud Health Holdings, Inc. [Member] | Trade name [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 10,800
Weighted Average Life (Years)	7 years
Silver Cloud Health Holdings, Inc. [Member] | Technology [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$ 34,996
Weighted Average Life (Years)	5 years
Conversa Health Inc. [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 34,700
Conversa Health Inc. [Member] | Customer relationships [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 10,100
Weighted Average Life (Years)		10 years
Conversa Health Inc. [Member] | Trade name [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 4,200
Weighted Average Life (Years)		5 years
Conversa Health Inc. [Member] | Technology [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired		$ 20,400
Weighted Average Life (Years)		5 years

Business Combinations - Schedul

Business Combinations - Schedule of Identifiable Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Aug. 27, 2021	Aug. 09, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Allocation of Consideration transferred:
Goodwill			$ 442,761	$ 193,877	$ 193,877
Silver Cloud Health Holdings, Inc. [Member]
Purchase consideration:
Payment to acquire business	$ 105,195
Stock consideration	85,571
Contingent consideration	29,360
Escrow share consideration	6,376
Working capital adjustment	(300)
Total consideration transferred	226,202
Allocation of Consideration transferred:
Accounts receivable	2,630
Identifiable intangible assets	78,146
Other assets	491
Total assets acquired	81,267
Current liabilities	2,155
Deferred revenue	5,813
Other long-term liabilities	11,557
Total liabilities assumed	19,525
Goodwill	164,460
Total purchase consideration	$ 226,202
Conversa Health Inc. [Member]
Purchase consideration:
Payment to acquire business		$ 51,331
Stock consideration		52,160
Contingent consideration		15,230
Working capital adjustment		(127)
Total consideration transferred		118,594
Allocation of Consideration transferred:
Accounts receivable		3,651
Identifiable intangible assets		34,700
Other assets		4,604
Total assets acquired		42,955
Current liabilities		8,463
Deferred revenue		4,655
Other long-term liabilities		115
Total liabilities assumed		13,233
Goodwill		88,872
Total purchase consideration		$ 118,594

Deferred Contract Acquisition_3

Deferred Contract Acquisition and Contract Fulfillment Costs - Summary of Capitalized Contract Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Contract Acquisition Cost [Member]
Capitalized Contract Cost [Line Items]
Beginning balance	$ 3,461	$ 2,769
Additions to deferred contract acquisition costs	2,235	2,102
Amortization of deferred contract acquisition costs	(1,971)	(1,410)	$ (1,062)
Ending balance	3,725	3,461	2,769
Deferred contract acquisition costs, current	1,697	2,134
Deferred contract acquisition costs, noncurrent	2,028	1,327
Contract Fulfillment Cost [Member]
Capitalized Contract Cost [Line Items]
Beginning balance	1,861	2,086
Additions to deferred contract acquisition costs	266	627
Amortization of deferred contract acquisition costs	(737)	(852)	(707)
Ending balance	1,390	1,861	$ 2,086
Deferred contract acquisition costs, current	736	624
Deferred contract acquisition costs, noncurrent	$ 654	$ 1,237

Deferred Contract Acquisition_4

Deferred Contract Acquisition and Contract Fulfillment Costs - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Contract Acquisition Cost [Member]
Capitalized Contract Cost [Line Items]
Amortization expense related to deferred costs	$ 1,971	$ 1,410	$ 1,062
Contract Fulfillment Cost [Member]
Capitalized Contract Cost [Line Items]
Amortization expense related to deferred costs	$ 737	$ 852	$ 707

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 13,974	$ 15,577
Less: Accumulated depreciation and amortization	(11,739)	(11,741)
Property and equipment, net	2,235	3,836
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	231	930
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	7,965	7,638
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	5,086	4,847
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 692	$ 2,162

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 16,089,000	$ 10,153,000	$ 7,761,000
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	2,160,000	$ 2,146,000	$ 1,769,000
Disposition of depreciated assets gross value	$ 1,851

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1	$ 193,877
Goodwill acquired	253,332
Currency translation adjustments	(4,448)
Ending Balance	$ 442,761

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 186,487	$ 76,680
Accumulated Amortization	(34,078)	(21,152)
Carrying Value	152,409	55,528
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	81,053	38,782
Accumulated Amortization	(16,842)	(11,380)
Carrying Value	$ 64,211	$ 27,402
Weighted Average Remaining Life	8 years 2 months 12 days	7 years
Contractor relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(247)	(206)
Carrying Value	$ 288	$ 329
Weighted Average Remaining Life	7 years	8 years
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 14,435	$ 300
Accumulated Amortization	(706)	$ (300)
Carrying Value	$ 13,729
Weighted Average Remaining Life	5 years 9 months 18 days	0 years
Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 90,464	$ 37,063
Accumulated Amortization	(16,283)	(9,266)
Carrying Value	$ 74,181	$ 27,797
Weighted Average Remaining Life	5 years	7 years 6 months

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 13,929	$ 8,007	$ 5,992
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Write off of intangible assets		$ 255

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 25,039
2023	25,039
2024	25,055
2025	25,039
2026	20,617
Thereafter	31,620
Carrying Value	$ 152,409	$ 55,528

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 21,572	$ 20,521
Professional services	8,766	6,832
Earned contingent consideration	15,000
Provider services	5,473	4,632
Other	7,900	10,150
Total	$ 58,711	$ 42,135

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail) - USD ($)	Jan. 31, 2011	Dec. 31, 2020	Nov. 30, 2017
Two Thousand and Eleven Line of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity	$ 5,000,000
Two Thousand and Eleven Line of Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument variable interest rate spread	1.25%
Two Thousand and Seventeen Amended Line of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity			$ 7,000,000
Line of credit net of current portion outstanding		$ 0

Stockholders' Equity - Converti

Stockholders' Equity - Convertible Preferred Stock (Detail) $ in Thousands	Dec. 31, 2019USD ($)shares
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	17,744,445
Shares Issued	14,061,508
Shares Outstanding	14,012,935
Liquidation Preference | $	$ 608,449
Carrying Value | $	$ 655,799
Series A [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	3,200,000
Shares Issued	3,178,650
Shares Outstanding	3,130,077
Liquidation Preference | $	$ 51,741
Carrying Value | $	$ 28,889
Series B [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	833,334
Shares Issued	787,725
Shares Outstanding	787,725
Liquidation Preference | $	$ 37,060
Carrying Value | $	$ 23,632
Series C [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	13,711,111
Shares Issued	10,095,133
Shares Outstanding	10,095,133
Liquidation Preference | $	$ 519,648
Carrying Value | $	$ 603,278

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Aug. 27, 2021shares	Aug. 09, 2021shares	Sep. 21, 2020USD ($)$ / sharesshares	Aug. 22, 2020USD ($)	Aug. 31, 2021$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)$ / sharesshares	Feb. 29, 2020USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Aug. 30, 2020shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized						100,000,000			100,000,000	100,000,000
Preferred stock per share | $ / shares						$ 0.01			$ 0.01	$ 0.01
Dividends Declared | $									$ 0	$ 0
Preferred stock, shares issued									0	0
Preferred stock, shares outstanding									0	0
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900 | $										$ 99,100,000
Shares withheld related to net share settlement | $										$ 37,405,000
Common stock authorized									1,300,000,000
Common stock reserve for issuance									61,989,749	61,392,747
Exercise of common stock options | $									$ 20,880,000	$ 5,912,000	$ 1,034,000
Expected volatility										52.00%	50.00%
Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued										45,681,499
Issuance of common stock in acquisitions, Shares									12,798,992
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900 | $										$ 56,000
Shares withheld related to net share settlement | $										$ 18,000
Share based Payment Arrangement Shares Withheld for Tax Withholding Obligations										1,805,073
Exercise of common stock options | $									$ 66,000	$ 23,000	$ 7,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of RSU's granted | $									152,550,000	195,655,000	15,135,000
Aggregate intrinsic value of restricted stock units vested | $									$ 90,726,000	73,836,000	1,693,000
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option vesting period									4 years
Stock option expiration period									10 years
Shares available for grant									31,470,984
Aggregate intrinsic value of stock options exercised | $									$ 106,407,000	$ 31,194,000	$ 2,433,000
Weighted-average grant date fair value of common stock | $ / shares									$ 0	$ 4.17	$ 2.81
Exercise of common stock options | $									$ 20,806,000	$ 5,932,000	$ 1,036,000
Executive Equity Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected stock based compensation | $									$ 23,644,000
Executive Equity Awards [Member] | Restricted Stock [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units issued									3,230,750
Share based payment award percentage of outstanding stock maximum									1.50%
Share price | $ / shares									$ 9.96
Expected volatility									60.00%
Executive Equity Awards [Member] | Restricted Stock [Member] | Chief Executive Officer [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fully-diluted outstanding capital stock						50.00%			50.00%
Executive Equity Awards [Member] | Restricted Stock [Member] | Chief Executive Officer [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based payment award percentage of outstanding stock maximum						0.75%			0.75%
2020 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserve for issuance									2,906,197			3,084,218
Share-based compensation arrangement by share-based payment award, discount from market price, purchase date									85.00%
Shares, issued under ESPP									178,021
Equity Award Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation | $									$ 80,121,000
Weighted-average period									2 years 10 months 24 days
Conversa [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business combination consideration in shares issued or issuable					4,700,000
Common stock fair value per share | $ / shares					$ 11.20
SilverCloud [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business combination consideration in shares issued or issuable					8,100,000
Common stock fair value per share | $ / shares					$ 10.51
IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares withheld related to net share settlement | $						$ 24,157,000
Series C Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued, price per share | $ / shares							$ 100	$ 75	$ 45		$ 75
Number of new stock issued							1,342,750	170,000			628,719
Proceeds from stock issuance | $							$ 134,275,000	$ 12,750,000			$ 47,154,000
Issuance cost | $							$ 750,000	$ 261,000			$ 1,318,000
Issuance of common stock in acquisitions, Shares											456,667
Conversion price per share | $ / shares									$ 5.11
Convertible Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible preferred stock outstanding						15,525,685
Value of convertible preferred stock | $						$ 801,813,000
Preferred stock conversion basis									8.8-to-1.0
Convertible preferred stock to common stock, conversion ratio						0.113			0.113
Common stock per share | $ / shares									$ 6.82
Proceeds from issuance of convertible preferred stock | $									$ 25,000,000
Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized						100,000,000
Series A Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued, price per share | $ / shares									$ 10
Conversion price per share | $ / shares									1.14
Series B Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued, price per share | $ / shares									30
Conversion price per share | $ / shares									3.41
Common Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued						45,681,499
Common stock per share | $ / shares						$ 0.01			$ 0.01	$ 0.01
Common stock per share | $ / shares						$ 18
Deferred offering cost | $						$ 4,906,000
Shares of common stock pursuant to the exercise of options						4,459,277
Net proceeds from IPO | $						$ 767,568,000
Underwriting discounts and commissions | $						$ 49,336,000
Common stock authorized						1,000,000,000			1,000,000,000	1,000,000,000
Common stock, voting rights									one
Common stock per share | $ / shares									$ 2,294
Common Class A [Member] | Conversa [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business combination consideration in shares issued or issuable		4,700,000
Common Class A [Member] | SilverCloud [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business combination consideration in shares issued or issuable	8,100,000
Common Class A [Member] | IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued, price per share | $ / shares			$ 18
Number of new stock issued			45,681,499
Convertible preferred stock outstanding			136,625,900
Net proceeds from IPO | $			$ 767,568,000
Underwriting discounts and commissions | $			$ 49,336,000
Common Class C [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued						5,555,555
Common stock per share | $ / shares						$ 0.01			$ 0.01	$ 0.01
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900 | $				$ 100,000,000		$ 99,100,000			$ 99,100,000
Purchase and issuance costs | $				$ 900,000		$ 900,000
Common stock authorized						200,000,000			200,000,000	200,000,000
Common stock, voting rights									one
Common stock per share | $ / shares									$ 56
Common Stock Class A And Class B [Member] | IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based Payment Arrangement Shares Withheld for Tax Withholding Obligations						1,340,354
Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock per share | $ / shares						$ 0.01			$ 0.01	$ 0.01
Common stock authorized						100,000,000			100,000,000	100,000,000
Common stock, voting rights									(x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power)
Number of shares converted									4,079,035
Common stock per share | $ / shares									$ 270

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	261,871,587
Shares Outstanding	261,871,587
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000	1,000,000,000
Shares Issued	229,402,453	201,488,097
Shares Outstanding	229,402,453	200,751,168
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000	100,000,000
Shares Issued	26,913,579	30,427,128
Shares Outstanding	26,913,579	29,297,382
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Activity

Stockholders' Equity - Activity under Plans (Detail) - 2020 Equity Incentive Plan [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, beginning of period	23,167,514
Number of Shares, Forfeited	(578,503)
Number of Shares, Exercised	(6,695,256)
Number of Shares, Outstanding, end of period	15,893,755	23,167,514
Number of Shares, Vested and expected to vest	15,395,398
Number of Shares, Options exercisable	13,407,882
Number of Shares, Outstanding, Weighted Average Exercise Price, beginning of period	$ 4.37
Number of Shares, Forfeited, Weighted Average Exercise Price	5.82
Number of Shares, Exercised, Weighted Average Exercise Price	3.21
Number of Shares, Outstanding, Weighted Average Exercise Price, end of period	4.81	$ 4.37
Number of Shares,Vested and expected to vest, Weighted Average Exercise Price, end of period	4.61
Number of Shares, Options exercisable, Weighted Average Exercise Price, end of period	$ 4.38
Number of Shares, Outstanding, Weighted Average Remaining Contractual Term (years)	5 years 10 months 24 days	6 years 2 months 12 days
Number of Shares, Vested and expected to vest, Weighted Average Remaining Contractual Term (years)	5 years 9 months 18 days
Number of Shares, Options exercisable, Weighted Average Remaining Contractual Term (years)	5 years 6 months
Number of Shares, Outstanding, Aggregate Intrinsic Value	$ 23,876	$ 487,758
Number of Shares, Vested and expected to vest, Aggregate Intrinsic Value	23,752
Number of Shares, Options exercisable, Aggregate Intrinsic Value	$ 23,120

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted Average of Assumptions used to Determine Fair Value of Common Stock Options Granted (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stockholders Equity Note [Abstract]
Risk-free interest rate	1.09%	2.17%
Expected term (in years)	6 years 1 month 6 days	6 years
Expected volatility	52.00%	50.00%
Expected dividend yield	0.00%	0.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Class of Stock [Line Items]
Shares, Unvested as of January 1, 2021 | shares	11,014,450
Shares, Granted | shares	9,011,024
Shares, Vested | shares	(7,394,144)
Shares, Forfeited | shares	(912,517)
Shares, Unvested as of December 31, 2021 | shares	11,718,813
Shares, Unvested, Weighted Average Grant Date Fair Value, as of January 1, 2021 | $ / shares	$ 14.43
Shares, Unvested, Granted, Weighted Average Grant Date Fair Value | $ / shares	16.93
Shares, Unvested, Vested, Weighted Average Grant Date Fair Value | $ / shares	9.34
Shares, Unvested, Forfeited, Weighted Average Grant Date Fair Value | $ / shares	13.62
Shares, Unvested as of December 31, 2021 | $ / shares	$ 19.63

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 43,809	$ 118,358	$ 12,135
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	1,655	1,087	536
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	7,613	4,793	1,477
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	7,666	4,147	2,418
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 26,875	$ 108,331	$ 7,704

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating Leases, Rent Expense	$ 5,870
Pending Litigation [Member]
Lessee Lease Description [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Lessee Lease Description [Line Items]
New Claims Filed, Number	0

Leases - Summary of Lease Cost

Leases - Summary of Lease Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
The components of lease cost under ASC 842 were as follows:
Operating lease cost	$ 5,617	$ 6,632	$ 6,649
Total lease cost	5,617	6,632	6,649
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows from operating leases	6,352	7,006	6,480
Right-of-use lease assets obtained in exchange for new operating lease liability:
Operating leases	15,506	417	$ 355
Operating leases
Operating lease right-of-use assets	16,422	6,609
Operating lease liability, current	1,918	6,357
Operating lease liability, net of current portion	14,694	1,296
Total operating lease liabilities	$ 16,612	$ 7,653
Weighted-average remaining lease term (in years)	5 years	1 year 3 months 18 days
Weighted-average discount rate	1.10%	2.90%

Leases - Summary of Minimum Fut

Leases - Summary of Minimum Future Lease Payments for These Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Years ending December 31,
2022	$ 2,100
2023	3,683
2024	3,416
2025	3,484
2026	3,554
Thereafter	893
Total lease payments	17,130
Less imputed interest	(518)
Total present value of lease liabilities	$ 16,612	$ 7,653

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Line Items]
Income tax (benefit) expense	$ (5,376,000)	$ 639,000	$ (803,000)
Percentage of change in ownership	50.00%
Unrecognized tax benefits related to uncertain tax positions	$ 0	$ 0
Federal Income Tax Authority [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 703,416,000
Operating loss carryforwards, expiration year	2026
Operating loss carryforwards indefinitely	$ 472,047,000
Federal Income Tax Authority [Member] | Research and Development [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforwards, amount	$ 1,602,000
Tax credit carryforwards, expiration year	2027
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 30,050,000
Operating loss carryforwards, expiration year	2022
State and Local Jurisdiction [Member] | Research and Development [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforwards, amount	$ 200,000
Tax credit carryforwards, expiration year	2027

Income Taxes - Summary of Compo

Income Taxes - Summary of Components of Current and Deferred Portions of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current income tax provision (benefit):
State	$ 41	$ 97	$ 34
Foreign	828	448	285
Total Current	869	545	319
Deferred income tax provision (benefit):
Federal	(5,730)	103	(821)
State	1	21	(252)
Foreign	(516)	(30)	(49)
Total Deferred	(6,245)	94	(1,122)
Total provision (benefit) for income taxes	$ (5,376)	$ 639	$ (803)

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Federal Statutory Rate and Provision for Income Taxes (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	21.00%	21.00%
State taxes, net of federal benefit	4.50%	2.00%	3.00%
Valuation allowance	(24.50%)	(13.30%)	(21.30%)
Stock-based compensation	1.90%	(9.50%)	(1.10%)
Other	0.10%	(0.50%)	(0.70%)
Effective income tax rate	3.00%	(0.30%)	0.90%

Income Taxes - Summary of Signi

Income Taxes - Summary of Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 179,555	$ 116,965
Research and development credit carryforwards	1,676	2,081
Deferred revenue	2,863	4,848
Deferred compensation	7,176	7,142
Startup costs	84	171
Leasing obligation	4,115	1,937
Other	904	1,030
Total deferred tax assets	196,373	134,174
Total valuation allowance	(164,391)	(118,795)	$ (88,499)	$ (69,433)
Total net deferred tax assets	31,982	15,379
Deferred tax liabilities:
Joint venture investment basis difference	(1,453)	(1,706)
Intangibles	(30,265)	(10,563)
Right-of-use assets	(4,068)	(1,669)
Other	(1,131)	(1,374)
Total deferred tax assets (liabilities)	(36,917)	(15,312)
Net deferred tax liabilities	$ (4,935)
Net deferred tax assets		$ 67

Income Taxes - Summary of Chang

Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Valuation Allowance [Abstract]
Valuation allowance as of beginning of the year	$ 118,795	$ 88,499	$ 69,433
Increases recorded to income tax provision	51,348	30,296	20,454
Decreases recorded as a benefit to income tax provision	(5,752)		(1,388)
Valuation allowance as of end of year	$ 164,391	$ 118,795	$ 88,499

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 30, 2021	Feb. 28, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Deferred revenue			$ 75,896	$ 74,800	$ 77,386	$ 93,299
Revenues recognized from related party			(122,621)	(112,128)	(101,080)
Payment to acquire interest in joint venture			2,548	2,940
Payment to executive officers for stock tax loans				16,441
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Due from related parties			1,613	0
Deferred revenue			1,426	1,496
Revenues recognized from related party			1,841	1,825
Payment to acquire interest in joint venture			2,548	$ 2,940
Equity method investment, ownership percentage				50.00%
Teva Pharmaceuticals Industries Ltd [Member]
Related Party Transaction [Line Items]
Due from related parties				$ 0
Philips Holding USA Inc [Member]
Related Party Transaction [Line Items]
Due from related parties				763
Deferred revenue				1,458
Revenues recognized from related party	$ 1,658			2,441	1,021
Anthem Inc [Member]
Related Party Transaction [Line Items]
Due from related parties				8,391
Deferred revenue				11,347
Revenues recognized from related party		$ 7,218		55,180	34,095
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Due from related parties			441	1,020
Deferred revenue			456	606
Revenues recognized from related party			$ 1,301	$ 1,357	$ 1,262

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Annual contributions per employee, amount	$ 2,698	$ 2,165	$ 1,966

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss	$ (176,782)	$ (228,626)	$ (88,366)
Net loss attributable to non-controlling interest	(448)	(4,194)	(1,176)
Net loss attributable to American Well Corporation	$ (176,334)	$ (224,432)	$ (87,190)
Denominator:
Weighted-average common shares outstanding, basic and diluted	254,068,942	99,044,312	41,138,798
Net loss per share attributable to common stockholders, basic and diluted	$ (0.69)	$ (2.27)	$ (2.12)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	23,366,542	28,567,136	150,553,114
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount			123,313,703
Unvested restricted stock units Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,472,787	5,399,622	2,322,408
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	15,893,755	23,167,514	24,917,003